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ABSTRACT 
Sixin Jiang 
STARCH-BINDING DOMAIN-CONTAINING PROTEIN 1:  
A NOVEL PARTICIPANT IN GLYCOGEN METABOLISM 
Glycogen, a branched polymer of glucose, acts as an intracellular carbon and 
energy reserve in many tissues and cell types.  The breakdown of glycogen by 
hormonally regulated degradation involving the coordinated action of glycogen 
phosphorylase and debranching enzyme has been well studied.  However, the 
importance of lysosomal disposal of glycogen has been underscored by a 
glycogen storage disorder, Pompe disease.  This disease destroys tissues by 
over-accumulating glycogen in lysosomes due to a genetic defect in the 
lysosomal acid α-glucosidase.  Details of the intracellular trafficking of glycogen 
are not well understood.  Starch-binding domain-containing protein 1 (Stbd1) is a 
protein of previously unknown function with predicted hydrophobic N-terminus 
and C-terminal CBM20 carbohydrate binding domain.  The protein is highly 
expressed in the liver and muscle, the major repositories of glycogen.  Stbd1 
binds to glycogen in vitro and in vivo with a preference for less branched and 
more phosphorylated polysaccharides.  In animal models, the protein level of 
Stbd1 correlates with the genetic depletion of glycogen.  Endogenous Stbd1 is 
found in perinuclear compartments in cultured mouse and rat cells.  When over-
expressed in cells, Stbd1 accumulates and coincides with glycogen and 
GABARAPL1, the autophagy protein.  They form enlarged perinuclear structures 
which are abolished by removing the hydrophobic N-terminus of Stbd1.  Stbd1, 
vii 
 
with point mutations in the CBM20 domain, retains the perinuclear localization 
but without concentration of glycogen in this compartment.  In cells that are 
stably over-expressing glycogen synthase, glycogen exists as large perinuclear 
deposits, where Stbd1 can also be present.  Removing glucose from the culture 
leads to a breakdown of the massive glycogen accumulation into numerous 
smaller and scattered deposits which are still positive for Stbd1.  Furthermore, 
the autophagy protein GABARAPL1 co-immunoprecipates and co-localizes with 
Stbd1 when co-expressed in cells.  Point mutation or deletion of the autophagy 
protein interacting region on Stbd1 eliminates the interaction and co-localization 
with GABARAPL1 but not the characteristic perinuclear distribution of Stbd1.  We 
propose that Stbd1 is involved in glycogen metabolism.  In particular, it 
participates in the vesicular transfer of glycogen to the lysosome with the 
recruitment of autophagy related proteins GABARAPL1 and/or GABARAP, as 
these vesicles mature prior to lysosomal fusion. 
 
Peter J. Roach, Ph.D., Chair 
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INTRODUCTION 
 
1. Glycogen and its metabolism 
 
1.1 Glycogen structure and function 
 
Glucose polymers are universally present in organisms from single cell 
microorganisms to humans, in the form of starch or glycogen.  The widely 
accepted role of glycogen is as an intracellular carbon and energy reserve.  As 
branched polymeric glucose, glycogen acts as a repository of the 
monosaccharide in many tissues and cell types [1, 2].  For whole body glucose 
homeostasis, the major storage of glycogen is in the liver and skeletal muscle but 
many other tissues are capable of synthesizing glycogen, such as heart, brain, 
kidney and adipose tissue.  In all tissues, glycogen serves as an energy reserve, 
providing fuel for muscular activity and in liver supplying glucose for export to the 
bloodstream to prevent low blood glucose.  In addition to its general metabolic 
function, glycogen has also been proposed to have other, more controversial 
roles.  For instance, glycogen was reported to be relevant in chromatin 
condensation and nuclus formation in Xenopus eggs [3].  However, in 
Saccharomyces cerevisiae, cell division was not impaired by lacking glycogen [4, 
5]. 
 
There are two types of glycosidic linkages between glucose units in glycogen. 
The formation of α-1,4-glycosidic linkages is required for polymer elongation, 
while the branch points are introduced by α-1,6-glycosidic linkages, at the C6-OH 
of one of every 8-12 glucose residues on average.  The frequency and 
distribution of branches determines glycogen topology, structure and solubility, 
and differentiates glycogen from amylopectin, the carbohydrate moiety of starch 
[6].  The Meyer-Bernfeld model of the branching structure of glycogen has been 
generally accepted and refined [7] (Figure 1).  In this model, a full size glycogen 
molecule is predicted to contain 55,000 glucose residues forming 12 tiers with a 
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diameter of ~40 nm and Mr ~107 [8].  These glucose chains can be classed as 
the outer A chains without branches and the inner B chains with two branch 
points.  The number and length of A chains and B chains are roughly equal, 
normally 13 glucose residues in each chain.   
 
Although there has been no experimentally determined three-dimensional 
structure, glycogen particles isolated from liver are classified in three different 
structure groups by electron microscopy (EM) [9].  The α-particles, with the 
typical rosette shape and relative molecular mass (Mr) ~108, are commonly 
present in liver.  The smaller globular β-particles (Mr ~107) found in muscle and 
are ~20-30 nm in diameter and considered to be subunits of α-particles.  The γ-
particles are even smaller, described as 3 nm-subunits of α and β-particles.   
 
Besides glucose, glycogen also contains minor components like glucosamine [10] 
and phosphate [11, 12].  Small amounts of glucosamine were found in rabbit and 
pig liver glycogen, but not in skeletal muscle and heart glycogen [10].  UDP-
glucosamine is considered to be the glycogen synthase substrate that 
incorporates glucosamine into glycogen [13].  Liver glycogen purified from rats 
injected with galactosamine showed as much as 10% glucose residues replaced 
by glucosamine in α-1,4-linkages [10].  Covalently bound phosphate has been 
detected in rabbit skeletal muscle glycogen [11, 12].  These phosphates were 
suggested to be present as a phosphomonoester at the C6 and a phosphodiester, 
which introduces an alternative branch point between C1-C6 linkages [14].  A 
specific enzyme, UDP-glucose: glycogen glucose-1-phosphotransferase was 
proposed to form the diester bond using phosphate from UDP-glucose.  However, 
the enzyme was not completely defined at the molecular level. 
 
So far, the physiological significance of these atypical, covalent structural 
components of glycogen has not been fully understood.  Recent studies in our 
laboratory proposed that hyperphosphorylation leads to abnormal glycogen 
structure [15], pointing to a critical role of covalent phosphate in maintaining 
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glycogen structure and solubility.  Furthermore, glycogen synthase has been 
shown to incorporate the β-phosphate of UDP-glucose into glycogen during 
synthesis forming covalent phosphate linkage at the C2 and C3 of glucose in 
mammalian glycogen [16].  Therefore, a glycogen damage/repair process has 
been proposed in which phosphates are introduced by error and removed by 
subsequent processing [16].  
 
 
Figure 1.  Glycogen structure and glycosidic linkages.   
Glycogen is shown in the upper panel in branched pattern with outer unbranched 
A chains and inner B chains containing two branch points.  The two types of 
glycosidic linkages are shown in the lower panel.  
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1.2 Subcellular distribution of glycogen 
 
Glycogen is mostly described as cytosolic but glycogen particles have been 
found by electronic microscopy close to intracellular membranes such as 
endoplasmic reticulum (ER) in liver [17] and sarcoplasmic reticulum (SR) in 
muscle [17, 18].  Glycogen is also present in the yeast vacuole [19] and the 
lysosomes of mammalian cells.  For example, about 10% glycogen was 
lysosomal in normal mammalian hepatocytes [20, 21].  This subcellular 
localization of glycogen would allow for a more complex metabolism and would 
suggest the presence of multiple glycogen pools.  The α-glucosidase activity in 
the lysozome is critical for glycogen degradation as well as glycogen 
phosphorylase action in cytosol [1].  
 
1.3 Glycogen metabolism  
 
Generally, glycogen metabolism is mainly regulated by the coordination of the 
rate limiting enzymes of  glycogenesis and glycogenolysis, i.e. glycogen 
synthase and glycogen phosphorylase, respectively.  An overview of glycogen 
metabolism is shown in Figure 2.  Glycogen synthesis is mediated by the 
combined actions of three enzymes, glycogenin (GN), glycogen synthase (GS) 
and the branching enzyme (BE).  The cytosolic degradation of glycogen which 
can be hormonal regulated and exercise mediated, requires the coordinated 
action of glycogen phosphorylase (GPh) and the debranching enzyme 
(DBE/AGL), while the acid-α-glucosidase (GAA) is essential for glycogen 
hydrolysis in lysosomes. 
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Figure 2.  Schematic model of Glycogen metabolism.   
HK/GK, hexokinase, glucokinase; PGM, phosphoglucomutase; G6Pase, glucose-
6-phosphatase; UGP, UDP-glucose pyrophosphorylase; GN, glycogenin; GS, 
glycogen synthase; BE, branching enzyme; GPh, glycogen phosphorylase; DBE, 
debranching enzyme; GAA, lysosomal acid α-glucosidase.  
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1.3.1 Glycogen synthesis 
 
After a meal, glucose is taken up by tissues and primarily converted to glycogen 
in skeletal muscle and liver.  This helps keep blood glucose levels from being 
excessively elevated.   
 
There are multiple glucose transporters in mammals that facilitate glucose entry 
into cells [22, 23].  They are different in regulation mechanisms and tissue 
distribution.  Many tissues constitutively express GLUT1 at a basal level.  In 
gluconeogenic tissues like liver and kidney, and in β-cells in the pancreas, 
glucose is taken into cells by the constitutively active GLUT2, which is 
independent of insulin regulation.  In insulin-sensitive peripheral tissues, such as 
muscle and adipose tissue, GLUT4 is the dominantly expressed isoform, which 
translocates from an intracellular localization to the plasma membrane upon 
insulin stimulation [24].   
 
Immediate conversion of intracellular glucose to glucose-6-phosphate (G6P) is 
mediated by hexokinase in muscle and glucokinase in the liver.    When 
abundant nutrients are present, the glucose-6-P is converted to glucose-1-
phosphate (G1P) by phosphoglucomutase (PGM).  Uridine diphosphate glucose 
(UDP-glucose), which serves as the substrate for glycogen synthesis, is then 
formed from G1P and uridine 5'-triphosphate (UTP) by the action of UDP-glucose 
pyrophosphorylase (UGP).   
 
In the 1930’s, glycogen synthesis was thought to be the reversal of glycogen 
degradation by phosphorylase using G1P as substrate [25].  However, a 
separate synthetic enzyme, glycogen synthase, was discovered in the 1950’s  
[26].  Studies of glycogen synthase suggested that a separate protein primer was 
required for glycogen synthesis, which led to the discovery of glycogenin in the 
1970’s. 
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1.3.1.1 Glycogenin (GN) 
 
Glycogenin (EC2.4.1.186), the unique self-glycosylating protein, belongs to the 
family 8 retaining glycosyltransferases (GT8).  It was found as the initiator of 
glycogen biosynthesis in the 1970’s [27, 28] and acts as catalyst, substrate and 
product at the same time.  The crystal structure of rabbit muscle glycogenin 
showed it to be a functional dimer of a 37 KDa subunit [29].  In humans, there are 
two isoforms of glycogenin.  Glycogenin-1, encoded by the GYG1 gene, is widely 
expressed especially in muscle.  A mutation in GYG1 gene that leads to the 
inactivation of self-glycosylation has been reported to cause glycogen depletion 
in skeletal muscle and accumulation of Periodic acid-Shiff (PAS)-positive material 
in cardiomyocytes leading to cardiomyopathy and cardiac arrhythmia [30].  
Glycogenin-2, encoded by GYG2 is limited to express in liver, cardiac muscle 
and pancreas [31].  
  
GN initiates the synthesis of glycogen through a series of self-glucosylations 
using UDP-glucose as substrate to form a short, ~10-residue glucose chain.  A 
C1-O-tyrosyl linkage is first formed at the tyrosine Y194 of GN and followed by 
the repeated formation of α-1,4-glycosidic linkages [32, 33].  The glucose 
oligomer then serves as a primer for the subsequent bulk glycogen synthesis [34, 
35].   
 
1.3.1.2 Glycogen synthase (GS) 
 
As a member of the family 3 retaining glycosyltransferases (GT3), glycogen 
synthase (EC2.4.1.11) is the rate limiting intracellular enzyme in glycogen 
biosynthesis.  It transfers the glucosyl group from UDP-glucose to the non-
reducing end of a glycogen molecule and releases UDP, thereby forming the α-
1,4-glycosidic linkages in glycogen (Figure 1 and 2).  In mammals, two isoforms 
of GS, encoded by the GYS1 and GYS2 genes, have been identified with 70% 
sequence identity [1].  One isoform is expressed in muscle and other tissues 
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while the other is liver specific.  Yeast GS also exists as two isoforms, 50% 
identical to mammalian sequences.  Plant starch synthetases and bacterial 
starch/glycogen synthases are distinguished from mammalian glycogen 
synthases in two aspects.  They use ADP-glucose instead of UDP-glucose as the 
glucosyl donor and they are not sensitive to G6P activation.  Although there is 
not much overall sequence similarity, two sequence motifs were found in 
common [36].  
  
GS activity is regulated by both reversible phosphorylation [37] and allosteric 
ligand binding, most importantly G6P.  In general, GS is inactivated by 
phosphorylation via protein kinases and the potent allosteric activator G6P 
overcomes this inactivation.  The ratio of the GS activities in the absence and 
presence of G6P can be used as a kinetic index of activation state [38].  The 
mammalian GS has two phosphorylation sites at the N-terminus and seven or 
five at the C-terminus, respectively, in the muscle and liver isoforms [1].  Various 
protein kinases has been reported to phosphorylate GS in vitro, such as 
glycogen synthase kinase-3 (GSK-3) [39, 40], phosphorylase kinase (PhK) [41], 
cAMP dependent protein kinase (PKA) [42], casein kinase 1 (CK1) [43, 44], 
casein kinase 2 (CK2) [45], AMP activated protein kinase (AMPK) [46], PAS 
domain-containing serine/threonine-protein kinase (PAS kinase) [47], dual 
specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) [48] and p38 
MAPK [49].  
 
When the inhibitory phosphates are removed from GS by glycogen-associated 
protein phosphatases1 (PP1Gs), GS is in an active state.  PP1Gs are composed 
of the catalytic subunit of protein phosphatase 1 (PP1c) and a regulatory or 
targeting subunit that binds glycogen by carbohydrate binding domains, which 
lock the phosphatase to glycogen to dephosphorylate enzymes participating in 
glycogen metabolism [50].  To date, four of the regulatory subunits, RGL, GL, PTG 
and PPP1R6 have been well studied, and three new putative sequences 
(PPP1R3E, PPP1R3F and PPP1R3G) have been identified by bioinformatic 
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approaches [51].  Besides a carbohydrate binding domain, they all have a PP1 
binding motif (RVXF) [52].  RGL (also called GM, encoded by PPP1R3A) was the 
first characterized glycogen-binding subunit [53].  The RGL subunit is restricted to 
striated muscle and is critical for GS activation in response to exercise [54].  A 
prevalent mutation in PPP1R3A impairs glycogen synthesis, thus decreasing 
glycogen levels in skeletal muscle of human and mouse [55].  GL (encoded by 
PPP1R3B), smaller than RGL, is primarily expressed in liver and skeletal muscle 
in humans but only in liver of rodents [56].  GL expression depends on insulin 
regulation and PP1-GL activity is allosterically controlled by glucose and 
phosphorylase [57, 58].  PTG (also called PPP1R5 or R5, encoded by PPP1R3C) 
has been reported to be expressed in various tissues and interacts with glycogen 
metabolizing enzymes like GS, GPh and PhK [59-61] .  PPP1R6 (R6, encoded 
by PPP1R3D), is widely expressed in tissues, with the highest levels in heart and 
skeletal muscle and much lower levels in the liver [62].  PPP1R3E (R3E, 
encoded by PPP1R3E) mRNA distribution is different in rat and human tissues. It 
is most abundant in rat liver and cardiac muscle, but barely detectable in human 
liver. This species-specific difference is similar to GL mRNA, which is highly 
expressed in human but not rodent skeletal muscle.  The activity of PP1-R3E 
was proposed to be under long-term control by insulin in rat liver [63]. 
 
The activated GS elongates the glucose chain which would eventually become 
insoluble and perhaps toxic to the cell.  The formation of branch points is 
necessary to keep the polymer soluble, thus requiring another important 
glycogen metabolic enzyme, the branching enzyme. 
 
1.3.1.3 The branching enzyme (BE) 
 
The branching enzyme (EC2.4.2.18), with amylo-1, 4 to 1, 6-transglucosidase 
activity, maintains the structure and solubility of growing glycogen particles by 
introducing polysaccharide α-1,6-glycosidic linkages as branch points.  
Specifically, the branching enzyme cleaves an α-1,4-glycosidic linkage, cuts off a 
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section of glucosyl units and reforms an α-1,6-bond [64].  The mammalian BE 
works as a monomer, ~77 KDa [65] and shows sequence similarity with other 
polysaccharide enzymes that modify branched structures, e.g. α-amylase.  The 
solubility of polysaccharides is determined by the branching frequency.  
Glycogen, branching is more frequent than amylopectin, making glycogen more 
soluble in aqueous solution.  Therefore, one important function of glycogen 
branching is to keep the glucose polymer functional and non-toxic to the cells.  
No regulation of the BE has yet been established.   
 
1.3.2 Glycogen degradation 
 
When energy is necessary, in times of fasting or exercise, glycogen is broken 
down to release glucose for metabolism.  Glycogen degradation happens in two 
ways.  One is the hormonal or exercise mediated pathway which requires 
glycogen phosphorylase and debranching enzyme [1].  The other process 
involves transfer of glycogen to the lysosome and the action of lysosomal acid α-
glucosidase (also named acid maltase).  The significance of the lysosomal 
hydrolysis pathway is underlined by the fact that defects in this glucosidase 
cause a severe glycogen storage disease, Pompe disease, which eventually 
destroys tissues by over-accumulating glycogen in lysosomes [2, 66].  The 
mechanism of glycogen delivery to the lysosome is not well understood, and may 
involve some vesicular trafficking mechanism such as occurs in autophagy [67, 
68].  
 
1.3.2.1 Glycogen phosphorylase (GPh) 
 
Glycogen phosphorylase (EC 2.4.1.1) (GPh) is affiliated with the family 35 
glycosyltransferases.  As one of the key enzymes in glycogenolysis, GPh drives 
the generation of glucose-1-phosphate and glycogen(n-1) by phosphorolytion and 
subsequent cleavage of the α-1,4-glycosidic linkages of glycogen (Figure 2).  In 
mammals, three isoforms of GPh have been defined, in skeletal muscle, liver and 
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brain [69].  Since the three dimensional structure of the mammalian muscle 
isoform has been solved, studies are able to correlate catalysis and regulatory 
mechanisms with protein structures [70].  The most active form of the enzyme is 
considered to be a homodimer of the 97 KDa subunit [71] which is able to 
transition between an active R state and a less active T state by phosphorylation 
and allosteric ligand interaction.  The phosphorylation triggers a conformational 
change so that the enzyme switches from the less active T state to the more 
active R state.  The more active form of the enzyme, phosphorylase a, is 
phosphorylated by PhK at a single serine residue, S14.  The protein phosphatase 
that is responsible for GPh dephosphorylation, much as described for GS 
dephosphorylation, is the PP1G, containing the RGL, PTG-R5 or R6 regulatory 
subunits in skeletal muscle and PTG-R5, R6 or GL in liver [72].  The allosteric 
activator AMP can restore activity to the dephosphorylated form of the enzyme, 
phosphorylase b, shifting back to the R state.  Negative allosteric effectors like 
G6P and ATP compete with binding sites for AMP in the muscle enzyme.  
Phosphorylase activity is measured in the absence and presence of its allosteric 
regulator AMP similar to that for glycogen synthase.  The resulting activity ratio is 
used as a kinetic index of enzyme activation on account of its covalent 
phosphorylation status [73].   
 
1.3.2.2 The debranching enzyme (DBE) 
 
The debranching enzyme (DBE, also called amylo-1,6-glucosidase, 4-α-
glucanotransferase, AGL) (EC 3.2.1.68) is a monomer, ~165 KDa [74].  When 
phosphorylase stalls four glucose residues from an α-1,6-brachpoint, the DBE is 
required for the continuation of glycogen degradation.  DBE contains two 
different active sites responsible for two individual catalytic activities [75].  The N-
terminal domain is an oligo-1,4-1,4-glucantransferase, in the family 13 of 
glycoside hydrolases (GHs) [76] with sequence similarity to α-amylase.  The N-
terminal domain hydrolyzes an α-1,4-glycosidic bound and links the detached 
glucose residues to the end of the main chain by a reformed α-1,4-linkage, 
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leaving a single branched residue at the α-1,6-branchpoint.  The C-terminal 
domain has amylo-1,6-glucosidase activity [75] that removes the remaining 
branched glucose residue.   
 
1.3.2.3 Acid-α-glucosidase (GAA) 
 
The acid-α-glucosidase (GAA) (EC 3.2.1.20), belongs to the family 31 
glycosylhydrolases and breaks down glycogen into glucose by hydrolyzing both 
α-1,4- and α-1,6-linkages.  The 76 kDa mature and active enzyme is generated 
from a 110 kDa precursor via proteolysis at both the N- and the C-termini [77].  
As a glycoprotein with seven sites of N-glycosylation [78], GAA shares significant 
sequence similarity to sucrase-isomaltase, a bifunctional enzyme and an integral 
membrane protein in the small intestine brush border membrane [79].  Some 
catalytically critical residues have been identified in a region of conserved 
sequence among α-glucosidase, sucrase and isomaltase catalytic domains [80].  
Transcriptional regulation of the human GAA gene has been reported [81], but 
the enzyme activity seems mostly to depend on pH. 
 
1.4 Regulation of glycogen metabolism 
 
Skeletal muscle and liver have the majority of glycogen deposits that are pivotal 
in whole body glucose homeostasis.   
 
1.4.1 Regulation in skeletal muscle 
 
As an insulin sensitive tissue, the conversion of glucose in skeletal muscle is 
largely regulated by insulin.  Insulin promotes glucose uptake by regulating 
GLUT4 translocation and stimulates phosphatidylinositol-3-kinase (PI3K) 
mediated signaling.  Increased glucose uptake results in an elevation of G6P 
levels, which activates glycogen synthase allosterically to stimulate glycogen 
synthesis.  In the signaling cascades, insulin first binds to the extracellular α-
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subunit of the insulin receptor (IR) to increase its tyrosine kinase activity.  Then a 
series of tyrosine residues in the intracellular β-subunit of the IR undergoes 
autophosphorylation that promotes phosphorylation of intracellular substrates, 
including the insulin receptor substrate 1/2 (IRS-1/2).  When IRS is 
phosphorylated by the IR, signals are passed down to PI3K, which then 
phosphorylates the 3’ position of phosphatidylinositol-4,5-bisphosphate 
(PI(4,5)P2) generating phosphatidylinositol-3,4,5-trisphosphate (PI(3,4,5)P3).  
PIP3 recruits the 3’-phosphatidylinositol dependent kinase 1 (PDK1) to activate 
protein kinase B (PKB/AKT) which suppresses GSK3 activity by phosphorylating 
an N terminal serine of the enzyme.  The inactivated GSK3 no longer 
phosphorylates sites 3a, 3b, 3c and 4 at the C-terminus of glycogen synthase 
and leaves the enzyme active.  Since insulin causes dephosphorylation of both 
the N and C terminal phosphorylation sites [82, 83], it seems that insulin control 
of GS cannot be explained only by the regulation of GSK-3.  It has been 
proposed that insulin stimulation activates PP1G with RGL [84] or PTG [60, 85].  
However, GS is still activated by insulin signaling in RGL knockout mice [86], 
implicating other targeting subunits of PP1 in insulin stimulated 
dephosphorylation of GS in muscle.  In the diabetic state, impaired muscle 
glycogen metabolism is associated with deficient insulin action [1].  
 
Epinephrine works antagonistically with insulin in muscle, stimulating 
glycogenolysis and inhibiting glycogenesis.  By interacting with β-adrenergic 
receptors, epinephrine activates adenylyl cyclase to convert ATP into cAMP.  
cAMP binds to the regulatory subunit of cAMP dependent protein kinase (PKA) 
and releases the active catalytic subunit to phosphorylate the α and β subunits of 
PhK.  The activated catalytic subunit of PhK phosphorylates its primary 
downstream target GPh, shifting it to the more active R state (a form), thus 
promoting glycogenolysis.  For glycogen synthesis inhibition, PKA 
phosphorylates GS at sites 2, 1a and 1b [1], and regulates PhK to phosphorylate 
site 2.  PKA dependent phosphorylation has been proposed to regulate PP1 by 
phosphorylating RGL leading to dissociation of the catalytic subunit PP1c, thus 
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reducing the activity of PP1G [87].  A second mechanism for PKA control is by 
phosphorylating inhibitor-1, a small protein inhibitor of PP1 that is effective only 
after phosphorylation [88].   
 
1.4.2 Regulation in the liver 
 
In the fed state, glucose follows its concentration gradient into liver via the 
GLUT2 glucose transporter which not controlled by insulin.  Glucokinase and GS 
play large part in determining the rate of glycogen synthesis [1].  Simultaneously, 
allosteric binding of glucose to the phosphorylated form of glycogen 
phosphorylase makes it a better substrate for PP1G-GL dephosphorylation. This 
provides a negative feedback control on glycogen degradation which also 
releases glucose [89].  Moreover, the glucose induced transition of 
phosphorylase a to the b form relieves its inhibition on PP1G-GL, leading to 
dephosphorylation and activation of glycogen synthase [89].  
  
When glucagon action predominates over insulin action in response to 
decreased blood glucose, liver first breaks down glycogen reserves before 
activating gluconeogenesis.  Glucagon activates liver adenylyl cyclase to 
increase cAMP levels which then promotes PKA dependent phosphorylation of 
GS, leading to its inactivation.  At the same time, PhK is activated by PKA 
phosphorylation resulting in phosphorylation and activation of phosphorylase.  In 
addition, activated phosphorylase (a form) inhibits GS activity by binding GL to 
modulate PP1G-GL phosphatase activity towards GS [58, 90].  Glucose-1-P is 
released by glycogen phosphorolysis and then converted to G6P by 
phosphoglucomutatse.  Glucose-6-phosphatase (G6Pase) converts G6P to 
glucose that can help maintain blood glucose levels and provide an energy 
supply for other tissues, such as the brain, where glucose is a critical energy 
source.   
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2. Diseases associated with glycogen metabolism 
 
Glycogen accumulation and consumption is closely correlated with the glucose 
metabolism and usage in individual cells as well as in the whole body.  Abnormal 
glycogen storage can be considered as both a result and a cause of several 
diseases.  Abnormalities in glycogen metabolism are linked to a number of 
diseases, including single gene defects like glycogen storage diseases, and 
more complex, multigenic disorders like type 2 diabetes.  
 
2.1 Glycogen storage disease type 0: Glycogen synthase deficiency 
 
Glycogen storage disease type 0 (GSD-0) was first identified as a GS deficiency 
resulting in infantile fasting hypoglycemia [91] coincident with high blood ketones, 
low alanine and lactate concentrations, as well as postprandial hyperglycemia, 
hyperlactatemia and hyperlipidemia [92].  GSD-0 is caused by autosomal 
recessive mutations in the GYS2 gene, which encodes the liver isoform of 
glycogen synthase.  In Gys2 null mice, liver glycogen is reduced by 95%.  These 
mice have mildly hypoglycemia, elevated basal gluconeogenesis and impaired 
insulin suppression of endogenous glucose production [93].  Mutation in the 
GYS1 gene, which encodes the muscle isoform of GS, was reported to cause the 
sudden cardiac death of an eight year old patient who collapsed during a bout of 
exercise [94].  Consistent with this observation, about 90% of Gys1 knockout 
mice died soon after birth most likely due to cardiac dysfunction [95]. 
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2.2 Glycogen storage disease type I:  von Gierke’s disease; Glucose-6-
phosphatase deficiency; Hepatorenal glycogenosis 
 
Glycogen storage disease type I (GSD-I) is autosomal recessive and has four 
subtypes corresponding to different defects in the G6Pase system.  GSD-Ia is 
caused by the defect of G6Pase catalytic subunit (G6Pase-α), encoded by G6PC, 
leading to over-accumulation of glycogen and lipids in liver, kidney and intestinal 
mucosa.  GSD-Ib is caused by the deficiency of G6P transporter (G6P 
translocase, G6PT).  Both GSD-Ia and Ib patients have hypoglycemic seizures, 
hepatomegaly, growth retardation and life-threatening lactic acidosis [96, 97].  In 
gluconeogenesis and glycogenolysis, G6P is translocated from the cytoplasm 
into the lumen of the ER by G6PT, where G6Pase hydrolyses it [97].  The 
released glucose is transferred into blood stream.  The failure of G6P 
dephosphorylation contributes to elevated levels of intracellular G6P that drives 
excessive glycogen accumulation accompanied by severe hypoglycemia [98].   
Both GSD-Ic and -Id are deficient in liver microsomal transport system, in which 
GSD-Ic lacks phosphate mobilization while GSD-Id is unable to transport glucose 
[99].  Most GSD-Ic and all GSD-Id patients reported so far have mutations on the 
same gene encoding G6PT as in the GSD-Ib patients, but are diagnosed 
differently in clinical and biochemical views.  Deficiency of a new microsomal 
phosphate transporter, the Na(+)/phosphate co-transporters 4 (NPT) has been 
suggested to affect some of the GSD-Ic patients [100]. 
 
2.3 Glycogen storage disease type II:  Pompe disease; Acid α-glucosidase 
deficiency; Acid maltase deficiency; α-1, 4-glucosidase deficiency 
 
A lysosomal storage disease, glycogen storage disease type II (GSD-II) is an 
autosomal recessive disorder caused by a deficiency in the lysosomal GAA.  
Based on the severity and onset time, patients of GSD-II can be divided into 
infantile, non-typical infantile, juvenile and adult forms [101].  In the infantile 
GSD-II, GAA is absent in all tissues, with severe hypotonia, cardiomegaly, 
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macroglossia, and mild hepatomegaly.  Glycogen over accumulation in the 
lysosomes of the cardiac and skeletal muscle, usually causes death within a year 
after birth.  The non-typical infantile type patients can survive longer than 12 
months with less severe cardiomyopathy and ventricular hypertrophy [102].  The 
juvenile form starts in the first decade, is associated with residual GAA activity 
and is accompanied by weakness in skeletal and respiratory muscles, and mild 
hepatomegaly [103].  The adult phenotype, usually defined by the onset in the 
third to sixth decade of life, is similar to the juvenile form but with higher levels of 
residual GAA activity and a slower development of skeletal muscle weakness 
[104]. 
 
The phenotype of the Gaa null mice approximately reproduces the human 
disease but with later progression of symptoms comparing to the onset of the 
human disease [105].  Crossing Gaa knockout mice with a transgenic mouse 
overexpressing a hyperactivated form of GS sped up the disease progression 
and generated structurally abnormal polyglucosan, similar to what is seen in 
patients with Lafora disease, glycogen storage disease type IV (Andersen’s 
disease) and type VII (Tarui’s disease) [66].  A mouse Gaa and Gys1 double 
knockout showed significant decrease in glycogen levels of the cardiac and 
skeletal muscle, a notable decline in lysosomal enlargement and formation of 
autophagic vesicles as well as a complete correction of cardiomegaly and 
improved exercise capacity [106].  These data suggest long-term inhibition of GS 
as a new approach to GSD-II treatment.  Treatments for GSD-II include 
recombinant GAA infusion which led to the approval of enzyme replacement 
therapy in 2006, and development of experimental therapies, such as adeno-
associated virus vector-mediated gene therapy [99].  
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2.4 Glycogen storage disease type III:  Cori disease; Forbes disease; 
Amylo-1,6-glucosidase deficiency; Glycogen debrancher deficiency 
 
Glycogen storage disease type III (GSD-III) is an autosomal recessive disorder 
caused by mutations in the AGL/DBE gene leading to defects in the glycogen 
DBE (AGL) [107].  GSD-IIIa affects both the liver and muscle in 80% of the GSD-
III cases and GSD-IIIb affects only the liver in nearly 15% [108, 109].  In rare 
cases, GSD-IIIc and GSD-IIId have also been reported as selective deficiencies 
in glucosidase and transferase activities respectively [110, 111].  Symptoms 
usually present during infancy with hepatomegaly, hypoglycemia, short stature, 
dyslipidemia, and in a few cases, slight mental retardation.  The aberrant 
glycogen has very short outer chains because the complete phosphorolysis by 
GPh requires the elimination of branch points. 
 
2.5 Glycogen storage disease type IV:  Andersen’s disease; Brancher 
deficiency; Amylopectinosis; Glycogen branching enzyme deficiency 
 
Mutations in the GBE1 gene which encodes branching enzyme cause glycogen 
storage disease type IV (GSD-IV) which is autosomal recessive and can be one 
of the most severe of the glycogen storage disorders [112].  The phenotypes of 
GSD-IV are very heterogenous, partly because of the existence of tissue specific 
isoenzymes.  In the canonical hepatic form, patients present with 
hepatosplenomegaly, progressive liver cirrhosis and failure to thrive [113].  In the 
multiple system involvement, defects in both muscle and liver are detected, 
including peripheral myopathy with or without cardiomyopathy, neuropathy, and 
liver cirrhosis [114].  The severity of the disease correlates with the polyglucosan 
accumulation level [115].  The polyglucosan has long unbranched chains 
resembling amylopectin structure, accompanied by a loss of solubility, eventually 
driving cellular dysfunction and degeneration.  Liver transplantation is the only 
effective treatment so far for GSD-IV patients with progressive liver disease [99].  
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2.6 Glycogen storage disease type V:  McArdle’s disease; 
Myophosphorylase deficiency; Muscle glycogen phosphorylase deficiency 
 
Glycogen storage disease type V (GSD-V) is caused by mutations in the PYGM 
gene encoding the muscle form of GPh.  Symptoms usually start in young 
adulthood, mild and with exercise intolerance and muscle cramps due to the lack 
of glucose release from glycogen degradation as fuel [116]. 
 
2.7 Glycogen storage disease type VI:  Hers disease; Liver glycogen 
phosphorylase deficiency 
 
Glycogen storage disease type VI (GSD-VI) is a rare form of GSD, caused by a 
deficiency in the the liver GPh which is encoded by PYGL gene. Patients 
manifest infantile hepatomegaly and growth retardation with symptoms usually 
relieved as the patients age [99]. 
 
2.8 Glycogen storage disease type VII:  Tarui disease; Muscle 
phosphofructokinasedeficiency; Glycogen storage disease of muscle 
 
The symptoms of glycogen storage disease type VII (GSD-VII) are muscle 
cramps and myoglobinuria with exercise similar to that observed in GSD-V 
(McArdle’s disease).  GSD-VII is autosomal recessive and caused by mutations 
in the PFKM gene, encoding the muscle isoform of phosphofructokinase.  
Phosphofructokinase (PFK) (EC 2.7.1.1.11) phosphorylates fructose-6-
phosphate to generate fructose-1,6-bisphosphate.  This reaction is a key 
regulatory step in glycolysis.  The deficiency in PFK causes accumulation of 
glycolytic intermediates that builds up G6P, the allosteric activator of GS, thus 
resulting in excessive glycogen synthesis [117].   
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2.9 Phosphorylase activation system defects: Phosphorylase kinase 
system defects; GSD-VIa, IX, X, or VIII) 
 
PhK contains four subunits (α, β, γ and δ) that are encoded by different genes on 
different chromosomes with tissue specific expression.  The α and β subunits are 
regulatory, the γ subunit has the catalytic activity, and δ is responsible for Ca2+ 
binding.  The two isoforms of the α subunit, muscle and liver, are both encoded 
by genes located on the X chromosome [118] while the genes encoding other 
subunits (β, γ and δ) are autosomal.  Based on tissue specificity and incidence, 
there are four main clinical variants, affecting liver only, liver and muscle, muscle 
only, and heart only [119].  The liver specific cases are categorized into two types, 
the autosomal recessive form and the X-linked deficiency which is subsequently 
divided into two subtypes, XLG-I and II.  As one of the mildest of GSD, X-linked 
liver phosphorylase kinase deficiency (XLG; X-linked liver glycogenosis type I 
and type II, formerly GSD-VIII or GSD-VIa) is similar to GSD-VI since both 
disorders demonstrate low phosphorylase activity in the absence of adenosine 
monophosphate (AMP) [99].  The autosomal liver and muscle phosphorylase 
kinase β-subunit deficiency leads to remarkable accumulation of glycogen in both 
liver and muscle, and is characterized by a distended abdomen due to significant 
hepatomegaly [120].  The γ-subunit has two isoforms, the muscle form and the 
testis/liver form.  Mutations in the gene for the liver isoform are linked to higher 
risk of cirrhosis [121]. 
 
2.10 Glycogen storage disease type XI: GSD-XI; Fanconi-Bickel Syndrome, 
FBS 
 
Glycogen storage disease type XI (GSD-XI) is a rare, autosomal recessive 
transmitted disorder, caused by defects in a glucose transporter, GLUT2.  The 
disease is defined by hepatorenal glycogen accumulation, fasting hypoglycemia 
accompanied by postprandial hyperglycemia and hypergalactosemia, proximal 
renal tubular dysfunction, rickets and growth retardation [99]. 
21 
 
2.11 Lafora disease 
 
Lafora disease (LD) is an autosomal recessive progressive myoclonic epilepsy, 
rare but lethal, with the onset usually in the second decade of life [122].  It is a 
neurodegenerative disorder and can also be considered a glycogen storage 
disease due to the formation of polyglucosan inclusion bodies with insoluble, 
poorly branched glycogen-like structures, known as Lafora bodies, in neural and 
other tissues.  The condition is characterized by epilepsy, myoclonus and 
dementia.  Mutations in either the EPM2A gene encoding a dual specificity 
phosphatase laforin or NHLRC1 (also known as EPM2B) encoding an E3 
ubiquitin ligase malin cause ~90% cases of LD [123].  The remaining cases may 
be caused by mutations in a third, unknown gene, or in the regulatory elements 
of the two known genes [124, 125].  Therapeutic approaches for LD at present 
are limited to symptomatic management of the epilepsy, myoclonus and other 
complications.  Most recent research on LD has been aimed at understanding 
the functions and relationships of laforin and malin in the disease progression, 
with the hope of finding future therapies [126]. 
 
3. Carbohydrate-binding modules 
 
3.1 Carbohydrate-binding module families 
 
A carbohydrate-binding module (CBM) is described as a contiguous amino acid 
sequence folding as a separate domain and with non-catalytic carbohydrate-
binding activity [127].  CBMs are usually present within large carbohydrate-active 
enzymes, which separate this class of carbohydrate-binding protein from other 
non-catalytic sugar binding proteins like lectins and sugar transport proteins.  
However, there are a few exceptions, such as CBMs in cellulosomal scaffolding 
proteins and examples of independent putative CBMs [128].   
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CBMs were first discovered as modules that bound cellulose from the bacterium 
Cellulomonas fimi [129] and the fungus Trichoderma reesei [130].  Thus, they 
were previously classified as cellulose-binding domains (CBDs).  However, since 
non-catalytic modules derived from glycoside hydrolase (GH) families were 
identified in 1999 that bound carbohydrates other than cellulose, the more 
inclusive term CBM has been used to reclassify these polypeptides [131].  CBMs 
generally come with carbohydrate hydrolases degrading insoluble 
polysaccharides.  Several CBM families include proteins that bind storage 
polysaccharide like starch and glycogen [131]. 
 
Since more and more modules are continually being discovered, the CBMs have 
been classified into different families based on amino acid sequence similarity, 
binding specificity and structure [127, 131].  Comprehensive classification data of 
CBMs are collected in the carbohydrate active enzymes database (CAZy) [132] 
(http://www.cazy.org/Carbohydrate-Binding-Modules.html).   
 
Up to 2010, 61 families of CBMs have been reported. Among them, three-
dimensional structures of representative members of 55 families have been 
determined.  The β-sheet turns out to be the most prevalent conformational 
element in the architecture of CBMs.  Based on the structures, CBMs families 
have been grouped into 7 fold families: β-sandwich, β-trefoil, oligonucleotide 
/oligosaccharide binding (OB) folds, hevein fold, cystein knot, unique and unique 
with hevein-like fold [128, 131, 133] (Table 1).  (1) The β-sandwich is the 
dominant fold group, which contains two β-sheets comprising 3-6 antiparallel β-
strands [134].  Based on their fold, this group is further divided into two sub-
families, the β-jelly roll fold and the immunoglobulin fold [128].  (2) The β-trefoil, 
which appears second in frequency, forming 6 hairpin turns by 12 strands of β-
sheet.  The overall fold, having a pseudo-3-fold symmetry, consists of a 6-
stranded β barrel with a triangular hairpin triplet cap [135].  (3) The OB fold 
shows a closed beta-barrel formed by a coiled 5-stranded β-sheet. This barrel is 
capped by an α-helix located between the third and fourth strands [136].  (4) The 
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hevein fold contains primarily coils along with 2 small β-sheets and a small helix 
region[131].   
 
Fold CBM families 
β-sandwich 2, 3, 4, 6, 9, 11, 15, 16, 17, 20, 21,22, 
25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 
35, 36, 40, 41, 42, 44,47,48, 51 
β-trefoil 13, 42 
cystein knot 1 
Unique 5,12 
OB fold 10 
Hevein fold 18 
Unique (hevein-like fold) 14 
Table 1. CBMs classification based on structure (fold).  
Adapted from Guillen D., Sanchez S. and Rodriguez-Sanoja R.  Appl Microbiol 
Biotechnol (2010) [133].  
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CBMs have also been classified into three types by functional similarity in ligand-
binding [128, 131, 133].  (1) Type A includes “surface-binding” CBMs, which bind 
to insoluble, highly crystalline polysaccharides like cellulose and/or chitin.  The 
aromatic amino acid residues at the binding sites have a planar conformation that 
interacts with the flat surface of cellulose or chitin crystals.  There is little or no 
affinity of type A class CBMs to soluble carbohydrates.  (2) Type B are “glycan-
chain-binding” CBMs.  Their binding sites are described as grooves or clefts 
comprising several subsites where the aromatic residues interact with individual 
polysaccharide chains.  The aromatic side chains form twisted or sandwich 
platforms for ligand binding.  The binding affinity is determined by the degree of 
polymerization of the carbohydrate ligand.  Type B CBMs are equipped to prefer 
single glycan chains over crystalline surfaces for interaction. (3) Type C are 
“small sugar binding” CBMs.  They are lectin-like and bind to mono-, di-, or 
trisaccharides due to steric restriction in binding sites.  (Figure 3) 
 
 
Figure 3.  Structures of CBMs classified into three types by functional 
similarity [133].   
(A) Type ACBM from Trichoderma reesei cellobiohydrolase I.  (B) Type B CBM 
from Cellulomonas fimi endo-1,4-glucanase C.  (C) Type C CBM from 
Thermotoga maritime xylanase 10A.    
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Studies of residues involved in binding sites suggest that aromatic amino acids, 
typically tryptophan, but also highly conserved tyrosine residues play a critical 
role in ligand binding.  And the ligand specificity is determined by the orientation 
of aromatic residues.  The binding structure is stabilized by strong Van der Waals 
force accumulated from interactions between aromatic residues and sugar rings.  
Hydrogen bonds formed by the side chain of other polar amino acid residues 
may also help the stabilization.  Proper topology of binding sites is responsible 
for efficient polysaccharide ligand recognition and binding [137].  Therefore, 
subtle changes lead to different ligand specificity in CBMs even with apparent 
similar structures.   
 
In a given protein, the localization of CBMs can either be C-terminal or N-terminal, 
and occasionally central, in between catalytic modules.  CBMs contain from 30 to 
about 200 amino acids, and exist as a single domain, or double or triple units 
arranged in tandem [127, 133].  CBMs are also discovered as single proteins by 
themselves, for instance, Ole e10 from olive pollen [138], CBP21 from Serratia 
marcesens [139], and E7 and E8 from Thermobifida fusca [140].   
 
Since carbohydrates are involved in various biological processes such as 
metabolism, energy storage, structural support, antibiosis, immunological 
functions etc, it is very important to understand the mechanism of protein-
carbohydrate interactions.  The key role of CBMs is carbohydrate recognition and 
specific binding.  In hydrolytic proteins, CBMs contribute to increase catalytic 
rates by introducing the catalytic module into the proximity of substrate and 
prolong the enzyme association with substrate.  In nonhydrolytic proteins, CBMs 
can serve as part of a scaffolding unit as in cellulosome. Some CBMs have been 
reported to be capable of nonhydrolytically disrupting polysaccharide structures 
[127, 131].  Studies also indicated that CBMs worked on surface/interfacial 
modification of cellulose fibers [127].  So far, the most common biological 
function of CBMs is to bind polysaccharide and promote efficient hydrolysis.  
However, other CBM-related functions have been continually discovered, such 
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as development and modification of plant cell wall, pathogen defense, virulence, 
and etc.  As more structures and families of CBMs have been discovered and 
studied, our knowledge in CBMs expands and practical applications of CBMs 
have been reported in different biotechnology fields, such as bioprocessing, 
targeting, cell immobilization, CBM engineering, analytical tools in research and 
diagnostics, bioremediation, and fiber modification [127]. 
 
3.2 Starch-binding domain 
 
Starch-binding domain (SBD), a group of CBMs that bind starch, has nine 
families at present, including CBM20, CBM21, CBM25, CBM26, CBM34, CBM41, 
CBM45 [141, 142], CBM48 and CBM53 [143].  Three-dimensional structures of 
all but CBM45 and CBM53 are known.  SBDs have been classified into different 
CBM families based on the diversity of amino acid sequences.  Despite the low 
sequence similarities, all SBDs analyzed display a similar architecture described 
as β-sandwich fold with immunoglobulin-like topology [143].  
 
3.2.1 CBM20 
 
The earliest discovered SBDs were in the CBM20 family, which has been the 
most studied family in this clan so far.  SBD was considered exclusively 
associated with microbial amylolytic enzymes for many years until more 
extensive sequence databases became available.  Sequences similar to the 
CBM20 family of SBD were identified by BLAST searches.  Orthologs or putative 
SBD sequences have been identified in a broad range of bacterial, fungal, 
archaea, plant or animal proteins.  There are nearly 400 records in the CAZy 
database of CBM20s, in which seven are from archaea, 231 are from bacteria, 
138 are from eukaryote and 21 are unclassifed.  These proteins can be 
intracellular or secreted, amylolytic or nonamyloytic.  Although these CBM20s 
belong to proteins with different catalytic modules and from diverse phylogenic 
origins, they are generally involved in starch or glycogen metabolism.  Usually 
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containing 90-130 amino acids, CBM20s have no absolutely conserved residues 
in the family by comprehensive sequence studies [141, 142, 144]. 
 
The three-dimensional structures of CBM20s display a twisted and open-sided β-
barrel structure built by several β-strands [145, 146] (Figure 4A).  Two individual 
starch-binding (or glucan-binding) sites are defined [142, 147].  The structure of 
the best studied CBM20, the glucoamylase (GA) SBD from the fungus 
Aspergillus niger,  was solved by nuclear magnetic resonance (NMR) in a free 
state or bound to β-cyclodextrin [146, 148].  Binding site 1, small and shallow 
with inflexible structure on binding, comprises W543, K578, W590, E591 and 
N595.  The aromatic rings of W543 and W590 form a rigid and shallow 
hydrophobic platform for stacking two units of α-1, 4- glucoses.  There is little 
conformational change of site 1 in the ligand bound state.  Binding site 2 consists 
of T526, Y527, G528, E529, N530, D554, Y556 and W563, covering a broader 
surface area for ligand binding and requiring significant conformational change.  
The pivotal aromatic residues Y527 and Y556 stick out from protein surface, 
quite different from site 1 where aromatic rings lie parallel.  Although W563 is 
unable to interact with ligand due to its lack of surface accessibility, it is critical in 
keeping contacts with different residues in and around binding site 2.  Since the 
two binding sites differ in structure and flexibility, a different functional role is 
suggested for each the site.  While Site 1 is indicated as the primary recognition 
site for starch, site 2 is suggested as the specific site to lock SBD on the starch 
surface.  Studies in cyclodextrin glucanotransferase (CGTase) [149], α-amylase 
[150] and β-amylase [151] also provided supportive data. 
 
Based on the tree-dimensional structures, consensus amino acids associated 
with starch binding have been analyzed.  At the beginning, the sequence 
alignment of eight species from bacteria and fungi revealed four areas of 
sequence similarity [152].  Eleven invariant amino acids were identified including 
three tryptophans, three glycines and single residues of proline, threonine, lysine, 
asparagine and leucine.  The conserved tryptophans were considered involved in 
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association to glucosyl residues via Van der Waals force and/or hydrogen 
bonding [137].  The glycines and proline, as well as threonine, lysine and 
asparagines were suggested to maintain the conformation of the polypeptide 
chain [152].  Nevertheless, not all those conserved amino acids appeared to 
have same importance with expanded research in broader collections of CBM20s.  
Binding site 1 carries two conserved trptophans, e.g. W543 and W590 in GA 
SBD from A. niger [153], as well as W643 and W689 (or W616 and W662 after 
the deletion of 27 amino acids of signal peptide) in CGTase SBD from the 
bacteria Bacillus circulans strain 251[154].  The most conserved region in the 
CBM20 motif is around the former tryptophan including residues LGxW.  These 
two tryptophans are not entirely invariant, but in the 103 sequences analyzed, 
none of them lacks both residues [142].  Binding site 2 contains one tryptophan 
aligning with W563 in GA SBD from A niger, and two tryrosines in some cases.  
One tyrosine aligning with Y527 in GA SBD from A. niger is found in 23.3% of the 
sequences analyzed, and the other one aligning withY556 shows in 43.7% of the 
sequences [143].  Besides the earlier mentioned 11 consensus residues, one 
phenylalanine aligning with F519 in GA SBD from A niger is conserved in 87.5% 
of the analyzed sequences, including SBDs from outside of amylolytic enzymes, 
e.g. animal laforin and starch-binding domain-containing protein1 (Stbd1).  
Different residues are found at this position such as leucine, isoleucine or valine 
in several bacterial β-amylase, and arginine in glucan, water dikinase 3 (GWD3) 
from the plant Arabidopsis thaliana [143].  Another highly invariant tryptophan, 
aligning with W615 in GA SBD from A niger is considered primarily for 
conformational maintenance, because the W615K mutant had poor stability [153].  
  
CBM20s were first discovered as C-terminally positioned.  However, some plant 
GWD3 and 4-α-glucanotransferases, in addition to a number of unknown 
eukaryotic proteins in sequence alignment studies, have an N-terminal CBM20.  
Therefore, CBM20s are described as prominently but not exclusively localizing at 
C-termini [143].  
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3.2.2 CBM21, CBM48 and CBM 53 
 
CBM21s are mainly N-terminally positioned and 90-140 amino acids long.  The 
representative CBM21 is in GA from Rhizopus oryzae [152] and one single lysine 
residue, K34 is invariant through the CBM21 family alignment [142].  The solved 
CBM21 structure demonstrates a β-sandwich fold and immunoglobulin-like 
composition [155] (Figure 4B), similar to the canonical CBM20 architecture.  
CBM21 has not been studied as intensely as CBM20, partly because the 
situation is more complicated in CBM21.  Most members in the CBM21 family are 
from unknown proteins of miscellaneous origins.  Only 10% of the sequences in 
this family are from microbial amylolyctic enzymes while a considerable number 
of the rest are eukaryotic protein phosphatases and/or their regulatory subunits, 
e.g. PTG involved in glycogen metabolism [51].  CBM21 has been suggested to 
form a clan with CBM20 through bioinformatic analysis [142].  Despite infrequent 
slight variations in structure, close evolutionary relationships among CBM20, 21, 
48 and 53 has been proposed by the alignment of 60 selected SBD sequences.  
Besides SBDs linked with catalytic subunits of bacterial or fungal GH families, 
protein domains in higher eukaryotes have also been analyzed.  The mammalian 
regulatory subunit (β-subunit) of AMPK [156] and the plant starch excess 4 
protein which has been reported to be a laforin-like phosphoglucan phosphatase 
[157, 158], are members of CBM48, and the three SBD repeats in the plant 
starch synthase III from A. thaliana have been included in the new CBM53 family.  
 
3.2.3 CBM25, CBM26, CBM34, CBM41 and CBM45 
 
CBM25 and CBM26 are structurally related, and both exist in the maltohexaose-
forming amylasefrom Bacillus halodurans.  The SBDs in CBM25 can be single or 
double units, while the CBM26 members usually appear as tandem repeats.  
CBM25 has two binding sites while CBM26 bears only one [141] (Figure 4C and 
D).  CBM34 family covers the N-terminal modules of the neopullulanase 
subfamily like neopullulanase, maltogenic amylase and cyclomaltodextrinase, 
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which are all closely related members of the GH13 family (Figure 4E).  CBM41 
contains mostly bacterial pullulanases of GH13 family as well as many undefined 
proteins [141] (Figure 4F).  A number of those pullulanases are from human 
pathogens with structures similar to that of CBM20 [159, 160].  On the contrary, 
members in CBM45 family are mainly originated from eukaryotic proteins, as the 
tandem N-terminal domains of plant α-amylases and α-GWD [141].  
 
Figure 4.  The structural features of SBD from individual CBM families [141].   
(A) The CBM20 from Aspergillus niger glucoamylase in complex with β-
cyclodextrin.  (B) The CBM21 from Rhizopus oryzae glucoamylase.  (C) The 
CBM25 from Bacillus halodurans maltohexaose-forming amylase.  (D) The 
CBM26 of Bacillus halodurans maltohexaose-forming amylase.  (E) The CBM 34 
of Thermoactinomyces vulgaris ‘α-amylase’ TVA I.  (F) The CBM41 of Klebsiella 
pneumoniae pullulanase.  The tryptophan and tyrosine residues involved in 
substrate interaction are colored blue in the binding site 1 and magenta in the 
binding site 2.    
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4. Starch-binding domain-containing protein 1 
 
Starch-binding domain-containing protein 1 (Stbd1), sometimes called 
genethonin 1, is a novel protein with unknown function.  The chromosomal 
location of the human gene is 4q24-q25.  Stbd1 was first identified by Bouju et al. 
in 1998 [161], as a striated muscle-enriched protein encoded by a novel gene 
registered in the Genexpress index.  The cDNA clone was termed GENX-3414, 
and was isolated from a human skeletal muscle cDNA library with a set of 1091 
cDNA clones [162].  Bouju et al. selected a 2117-bp cDNA clone from the library 
as a northern blot probe and an mRNA about 2.4 kb was detected in different 
human tissues with high level in skeletal and cardiac muscles, and moderate 
levels in liver and placenta.  No hybridization with mRNA was detected in 
pancreas, kidney, lung and brain according to the report.  With successful 
isolation and sequencing of the full-length cDNA for the human GENX-3414 
transcript, their studies of the protein product provided some initial information.  
From sequence analysis, they pointed out a hydrophobic segment at the N-
terminus, a possible internal leucine-zipper motif, and several potential post-
translational modification sites, such as N-linked glycosylation, myristoylation and 
phosphorylation.  Immunoblot of human tissue extracts from skeletal muscle, 
heart and placenta showed a single or double-band protein with the apparent 
molecular masses of 41-43 KDa.  The protein was detected at high 
concentrations in membrane-enriched preparations of muscle, but not in the 
purified myofibrillar preparations.  Immunofluorescence analysis showed the 
protein was present within the cytoplasm and not at the peripheral sarcolemmal 
membrane.  These data so far suggested the protein was preferentially localized 
to the internal membrane systems (T-tubules and junctional sarcoplasmic 
reticulum) of the skeletal muscle.  
  
In 2002, Janecek [163] described the same protein which he referred to as 
genethonin, in a bioinformatics analysis focusing on the conserved starch-binding 
domain (SBD).   The growing databases raised the interest of searching SBD-
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related sequences in proteins other than amylase and of non-microbial origin, 
especially when an SBD-like sequence was reported at the N-terminus of laforin 
[164], a human protein involved in the progressive myoclonic epilepsy, Lafora 
disease.  By BLAST searches, human Stbd1 (genethonin) was identified to 
contain higher than 25% identity to SBD from the CBM20 family and has the 
classical C-terminal position of the SBD found in microbial amylases [163].  The 
tryptophan residues that are important to the structure and function of SBD from 
B. circulans strain 251 CGTase (W616, W 636, W662 and W684) [145, 148, 154] 
and A. niger GA (W563, W590, W615) [153, 165] are conserved in Stbd1(W293, 
W307, W334, W355) [163].  Homology modeling of 3-dimentional structure 
features of the C-terminus of human Stbd1 showed strong resemblance to the 
template structure of SBD from Bacillus sp. Strain 1011 CGTase (Figure 5), in 
the number and mutual orientation of β-strands and the side-chain orientation of 
the three tryptophans involved in starch-binding sites 1 and 2 [163].  
 
Figure 5.  Structures of conserved SBDs [163].   
(A) X-ray crystal structure of the Starch-binding domain from Bacillus. sp strain  
1011 cyclodextrin glucanotransferase (CGTase).  Starch-binding site 1 includes 
W616 and W662; Starch-binding site 2 includes W636; W684 serves primary 
structural role.  (B) Homology modeling structure of the C-terminal part of human 
Stbd1.   
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Although a carbohydrate-binding function of Stbd1 was indicated by the 
bioinformatics analysis, little work has addressed this protein until recently.  In 
2010, Stbd1 was identified by two different proteomic analyses.  Stapleton et al. 
[166] analyzed hepatic glycogen particle and identified Stbd1 as a protein 
associated with glycogen in both mouse and rat liver.  Behrends et al. reported 
Stbd1 as one of 67 high-confidence candidate interaction proteins (HCIPs) in an 
autophagy interaction network in human cells [167].  Our data on Stbd1 structure, 
subcellular distribution and functional analysis (see Results) provide more 
detailed insight into this novel protein [168].  
 
5.  Autophagy   
 
Autophagy, or autophagocytosis, is a collection of catabolic processes involving 
the delivery and degradation of a portion of the cytoplasm through the lysosomal 
machinery (Figure 4).  The process involving bulk segregation of cellular 
constituents in mammalian cell was first reported in 1957 [169].  Ultrastructural 
changes were observed in rat liver following glucagon injection, and based on 
that, autophagy was first introduced as a term by De Duve et al. in the 1960s 
[170, 171]. 
 
Although autophagy has been studied in mammalian cells for many years, insight 
into the molecular mechanism was first revealed in the yeast Saccharomyces 
cerevisiae which is genetically tractable.  The yeast vacuole, comparable to the 
lysosome in mammalian cells, is an acidic compartment containing hydrolytic 
enzymes.  Since 1997, 32 autophagy-related (ATG) genes have been identified 
in yeast, named from ATG1 to ATG32.  Most ATG genes are involved in 
autophagosome formation and are well conserved from yeast to mammalian 
systems [172].  The proteins encoded by ATG genes (Autophagy-related gene) 
are shared in nonspecific autophagy, specific and biosynthetic cytoplasm-to-
vacuole targeting pathway (Cvt), and selective breakdown of peroxisomes and 
mitochondria [173]. 
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A variety of autophagic processes exist, all having in common the degradation of 
intracellular components via the lysosome.  According to the ways substrates 
reach the lysosome, three major forms of autophagy have been described: 
macroautophagy, microautophagy and chaperone-mediated autophagy [174] 
(Figure 6).   
 
 
 
Figure 6.  Schematic models of three forms of autophagy. 
(A) Macroautophagy.  (B) Microautophagy.  (C) Chaperone-mediated autophagy.  
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5.1 Macroautophagy 
 
Macroautophagy, usually just referred to as autophagy, involves the formation of 
an autophagosome, a double -membrane structure that surrounds a targeted 
region of the cell, separating the contents from the rest of the cytoplasm. The 
resultant vesicle then fuses with a lysosome that subsequently degrades the 
contents.  ER is generally considered as one source of the sequestering 
membrane, whereas the phagophore or preautophagosome (also called isolation 
membrane), a unique hypothetical compartment is thought as membrane donor, 
[175, 176].  The macroautophagy process can be divided into several steps: 
omegasome (shaped like Ω) formation, the initiation and elongation of isolation 
membrane/phagophore, autophagosome formation, autophagosome-lysosome 
fusion, and degradation [172] (Figure 6A).  
  
5.1.1 Omegasome formation 
 
mTOR, a serine/threonine kinase, negatively regulates autophagy by 
phosphorylating Atg13, a component of ULK protein kinase complex which is 
required for autophagy induction and activity.  The complex contains unc-51 
kinase like protein (ULK, serine/threonine kinase, Atg1), Atg13, focal adhesion 
kinase family interacting protein of 200 KDa (FIP200) and a new mammalian 
autophagy protein Atg101.  The omegasome, shaped like the Greek letter Ω, is 
from the ER and contains the double FYVE-domain (Phe-Tyr-Val-Glu) containing 
protein 1 (DFCP1) which resides in ER and Golgi under nutrient-rich conditions.  
Binding to phosphatidylinositol-3-phosphate (PI(3)P), the DFPC1-positive 
omegasome formation is regulated by a class III PI3K complex, which includes 
Atg14, Vps34 (the catalytic subunit of PI3K), Vps15 (the regulatory subunit of 
PI3K) and beclin 1 (Atg6) [172].   
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5.1.2 Initiation and elongation of isolation membrane 
 
The isolation membrane is initiated inside the ring of the omegasome and its 
elongation requires the protein complex composed of the transmembrane protein 
Atg9 and the hypothetical WD-repeat protein interacting with phosphoinositides 
(WIPI-1, Atg18) [172].   
 
5.1.3 Autophagosome formation 
 
The autophagic machinery is conserved in the higher eukaryotes, therefore, 
breakthroughs in the study of yeast systems provide valuable insights into 
mammalian systems [177].  It has been reported that the human orthologs of 
Atg12 and Atg5 showed conjugation in a similar system to that of the yeast (see 
below for details described in Atg12 conjugation systems) [178].   
The formation of autophagosomes involves three steps: nucleation, expansion 
and completion [179].  The central machinery of autophagosome formation 
includes two ubiquitin-like (UBL) conjugation systems involving two UBL proteins, 
Atg12 and Atg8 (which is microtubule-associated protein 1 light chain 3, 
MAP1LC3 or LC3, LC3B in mammalian systems) respectively [177, 179].  The 
Atg12-Atg5-Atg16 complex is recruited to the isolation membrane mainly at the 
external surface and brings Atg8/LC3 to the site where 
phosphatidylethanolamine (PE)-conjugated Atg8/LC3 helps the expansion of the 
isolation membrane initiation.  When autophagosome formation is completed, the 
Atg8/LC3 is cleaved off from the PE containing outer surface by the protease 
Atg4, and Atg12-Atg5-Atg16 complex also dissociates from the completed 
vesicle [179]. 
 
In the Atg12 conjugation system, the hydrophilic Atg12 forms a covalent complex 
with Atg5 through G186, the C-terminal amino acid of Atg12 and K149 in the 
center of Atg5 [180].  Atg12 is first activated by Atg7, an E1-like enzyme. A 
thioester bond is formed between the C-terminal G186 of Atg12 to C507 of Atg7.  
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Then, Atg12 is transferred to C133 of an E2-like enzyme, Atg10, also forming a 
thioester bond [181].  Atg12 is ultimately conjugated to Atg5 via an isopeptide 
bond at K149.  Since no enzyme is recognized to cleave that bond, this 
conjugation is considered to be irreversible.  No E3-like enzyme is involved in 
this process.  A small protein Atg16 further binds to Atg5, and then Atg12-Atg5-
Atg16 forms a multimeric complex, possibly a tetramer, by homo-oligomerization 
via the coil-coil region in Atg16 [182].  (Figure 7) 
 
In the Atg8 conjugation system, the 117 residue basic protein Atg8 is modified at 
its C-terminal residue, by conjugation with PE [183].  First, R117 of the nascent 
protein is cleaved by a cysteine protease Atg4.  Then a thioester bond is formed 
between the exposed G116 on Atg8 to the C507 on Atg7, the E1-like enzyme.  
Next, Atg8 is delivered to Atg3, the E2-like enzyme, still through a thioester bond 
at C234.  Finally, PE is attached to G116 of Atg8 by an amide bond and is 
targeted to membranes.  It has been reported that the Atg12-Atg5 conjugate is 
required for Atg8 to localize to phagophore-assembly sites (pre-autophagosome 
structure, PAS) [184] and for Atg8-PE conjugation, possibly by an E3-like activity 
[185].  But no HECT or RING finger domain, which is typical of E3 ligases, has 
been identified in Atg12-Atg5 [179].  The conversion of free Atg8 to Atg8-PE 
proceeds when autophagy is induced.  The lipidation is reversible as Atg8-PE is 
able to release free Atg8 by Atg4 cleavage [186].  (Figure 7)  
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Figure 7.  Schematic models of ubiquitin-like conjugation system for 
autophagosome formation in yeast.   
(A) Atg-12-Atg5 conjugation system.  (B) Atg8 conjugation system. PE, 
phosphatidylethanolamine.   
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5.1.4 Function 
 
Studies have shown that macroautophagy is a tightly-regulated process that 
plays an important part in many physiological and pathological processes [174, 
187, 188].  One role is to maintain cellular homeostasis, since autophagic 
degradation of cellular constituents efficiently recycles essential nutrients to 
sustain basic biological processes.  Macroautophagy is required for normal 
development, in processes such as cellular differentiation, tissue remodeling and 
growth control.  It is also used as a defense mechanism for cell adaptation to 
adverse environments, e.g. response to starvation, anti-aging mechanisms, and 
innate immunity.  Deregulation of autophagy has been proposed to play a role in 
various diseases, including cancer, cardiomyopathy, muscular diseases, and 
neurodegenerative disorders. 
 
Many questions about the process and the mechanism remain to be elucidated.  
There is mTOR dependent macroautophagy under nutrient deprivation conditions 
as well as mTOR independent basal autophagy for housekeeping or during 
myotube differentiation [189].  Bypass of the essential Atg5/Atg7 in 
autophagosome formation and autophagy-mediated protein degradation has also 
been reported in mouse embryonic fibroblast (MEF) cells and embryonic tissues 
[190].  The role of macroautophagy in disease is not well characterized either.  It 
may help to halt the progression of some diseases and plays a protective role 
against intracellular pathogens [191], whereas in other situations, it may actually 
contribute to the development of a disease. 
 
5.2 Microautophagy 
 
In microautophagy, the cytoplasm is engulfed directly at the lysosomal surface, 
by invagination, protusion, and/or septation of the lysosomal limiting membrane.  
This process forms intralysosomal, single-membrane vesicles that are degraded 
by the lysosome [174].   
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5.3 Chaperone-mediated autophagy 
  
In chaperone-mediated autophagy (CMA), the substrates to be degraded in 
lysosomes are soluble cytosolic proteins and usually possess a KFERQ motif 
(Lys-Phe-Glu-Arg-Gln).  They are associated with a protein complex containing a 
cytosolic chaperone protein, the heat shock cognate protein of 70 KDa (hsc70) 
and a group of co-chaperones, which together help the protein substrates target 
to the receptor, lysosome-associated membrane protein type 2a (LAMP-2A).  
Multiple molecules of single-span transmembrane protein LAMP-2A together with 
lysosomal hsc70 are organized at the lysosome membrane to mediate 
translocation of protein substrates into the lysosomal lumen [192].  CMA has 
been considered to control normal cell functions and to supply energy in respond 
of nutritional stress, by clearing long-lived proteins.  Dysfunction of CMA has 
been related to a variety of diseases, such as lysosomal storage diseases, 
nephropathies and neurodegenerative disorders [192].  The reduced occurrence 
and/or diminished activity of CMA with aging are thought as a major aggravating 
factor in some diseases, particularly neurodegenerative disorders.  Study of the 
changes in CMA under pathological conditions could provide a potential 
therapeutic strategy [193]. 
 
5.4 Selective autophagy  
 
In addition to CMA, growing evidence suggests that selective removal of protein 
aggregates, organelles, and microbes in cells is mediated by a macroautophagy 
process.  A cargo receptor/adapter is required to connect the substrate to be 
degraded and the autophagasome proteins [194].  In yeast, selective cargo 
transportation to lysosome is demonstrated by the biosythetic Cvt pathway in 
which Atg19 plays the role of cargo receptor.  Atg19 binds to two lysosomal 
enzyme precursors, the α-mannosidase (Ams1) and the dodecameric aggregate 
of aminopeptidase 1 (Ape1) as well as a critical autophagosome formation 
protein Atg8, forming Cvt complex.  The complex is transported by Atg11 to PAS 
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where the double membrane is recruited and surrounds the complex [195].  Also, 
the selective disposal of peroxisomes requires autophagic receptor Atg30 in 
Pichia pastoris, and the removal of damaged mitochondria in S. cerevisiae needs 
Atg32 [196].  In mammalian cells, macroautophagy was thought to be a fairly 
unselective process.  However, recent reports have identified several selective 
autophagy processes such as aggrephagy that removes protein inclusions called 
aggrosomes, pexophagy, mitophagy, reticulophagy and ribophagy dealing with 
different organelles, corresponding to peroxisomes, mitochondria, surplus ER 
and ribosomes respectively,  lipophagy for oxidized lipid degradation, and 
xenophagy that eliminates intracellular pathogens like bacteria and viruses [194, 
197].   
 
Cargo receptors have been proposed to play a key role in each selective 
autophagy process.  Sequestosome protein-1 (SQSTM1), also widely known as 
ubiquitin-binding protein p62, has been considered a cargo receptor for 
autophagic degradation of ubiquitinated protein substrates.  SQSTM1/p62 is 
addionally a participant in Parkin-mediated mitophagy and in both vacuolar and 
cytosolic bacteria removal in which SQSTM1/p62 serves as a cooperator of 
calcium binding and coiled-coil domain 2 (CALCOCO2) also called antigen 
nuclear dot 52 kDa protein (NDP52) [194].  The much less studied next to 
BRCA1 gene 1 protein (NBR1) has been identified as a cargo receptor working 
as a SQSTM1/p62 partner in disposal of misfolded proteins [198].  The 
BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L) which is 
also known as NIP3-like protein X (Nix) has been reported as a selective 
autophagy receptor for the clearance of mitochondria in a ubiquitin independent 
manner [199].  Expanding knowledge of selective autophagy would assist study 
and discovery of drug targets for various diseases like cancer, 
neurodegenerative diseases, diabetes and infections.   
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6. Atg8 family 
 
The most conserved Atg protein, Atg8 has been suggested to have six 
mammalian orthologs.  All Atg8 orthologs have the conserved glycine at their C-
termini where PE modification, a key step in autophagosome formation, occurs.  
Based on homology of amino acid sequences, the Atg8 family has been divided 
into two subgroups [200].  Microtubule-associated protein 1A/1B-light chain 3 
(MAP1-LC3) A, B and C have been grouped into the LC3 subfamily in which 
LC3A has two alternative splicing isoforms, a and b.  γ-aminobutyric acid (GABA) 
A receptor-associated protein (GABARAP), GABARAP-like 1 (GABARAPL1), 
GABARAP-like 2 (GABARAPL2, also called golgi-associated ATPase enhancer 
of 16 kDa, GATE-16) have been placed in the GABARAP subfamily.  A recent 
report proposed that the LC3 subfamily is more involved in isolation membrane 
elongation while the GABARAP subfamily plays a crucial part in autophagosome 
maturation [200].  The mouse Atg4b, a mammalian ortholog of yeast Atg4, has 
been found to act on the C termini of Atg8 orthologs using its active-site cysteine.  
Although the amino acid sequences of these Atg8 orthologs differ from one 
another by as much as 70%, their affinities for Atg4b were roughly comparable in 
competition experiments [201].   
 
6.1 Microtubule-associated protein 1A/1B-light chain 3 (MAP1-LC3 or LC3) 
 
LC3 was the first mammalian ortholog of Atg8 to be identified, in rat.  There are 
four human LC3 proteins varying from 121 to 147 residues in length, which 
includes LC3A with two splicing isoforms, LC3B and LC3C.  To date, only LC3B, 
the 125-residue protein has gained extensive attention and is commonly used to 
monitor autophagy since the cytosolic LC3 (LC3-I) can be lipidated during 
autophagy to LC3-PE (LC3-II) and incorporated into autophagosome membranes 
[202].  The two forms of LC3 are detectable by immunoblotting or 
immunofluorescence methods.    
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6.2 γ-Aminobutyric acid (GABA) A receptor-associated protein (GABARAP)  
 
Type-A receptors for the neurotransmitter GABA (gamma-aminobutyric acid) are 
ligand-gated chloride channels that mediate inhibitory neurotransmission.  Each 
subunit of the pentameric receptor protein has a large intracellular loop that is 
phosphorylated [203] and may be required for sub-cellular targeting and 
membrane clustering of the receptor, perhaps by anchoring the receptor to the 
cytoskeleton [204, 205]. 
 
Using the intracellular loop of the GABAA receptor γ-2S subunit (GABRG2) as 
bait, Wang et al. [206] identified a cDNA encoding GABA receptor assocated 
protein (GABARAP) by yeast two-hybrid screens of a fetal brain cDNA library and 
an adult brain cDNA library.  Sequence analysis predicted that the 117-amino 
acid, 13.9-kDa GABARAP protein contains a basic N terminus and an acidic C 
terminus, with pI of 9.6.  In vitro binding assays showed that the N-terminal 21 
amino acids of GABARAP formed an α-helix that interacted with tubulin.  
Immunoprecipitation and immunohistochemical analysis in rat brain tissues 
demonstrated association and colocalization of GABARAP and GABAA receptors.  
Northern blot analysis detected a 0.9-kb GABARAP transcript in all tissues tested, 
namely heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas. 
Western blot analysis also showed a ubiquitous presence of GABARAP, 
suggesting that GABARAP is also involved in biologic events other than 
interaction with GABAA receptors. 
 
As one of the mammalian orthologs of yeast Atg8, GABARAP is about 30% 
identical to LC3 [206].  Kebeya et al. [207] demonstrated that GABARAP also 
generates a form II state, possibly by PE conjugation similarly to what happens to 
LC3 during autophagy.    
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6.3 GABARAP-like 1 (GABARAPL1) 
 
GABARAP-like 1 (GABARAPL1) was also named previously as glandular 
epithelial cell protein 1 (GEC1) or murine Atg8L/Apg8L. 
 
Through a differential screen of estrogen-regulated sequences expressed in 
quiescent guinea pig endometrial glandular epithelial cells (GEC), Pellerin et al. 
[208] cloned guinea pig Gabarapl1, naming it, after the cell they used, Gec1.  
Using the guinea pig sequence as probe, Vernier-Magnin et al. [209] cloned 
human GABARAPL1 which they called GEC1, from a placenta cDNA library.  
GABARAPL1 is a 117-amino acid protein with the same size of GABARAP and 
87% identity.   
 
By Northern blot analysis of human tissues, a 2.3-kb GABARAPL1 transcript was 
detected in all tissues examined, with highest levels in brain, heart, peripheral 
blood leukocytes, liver, kidney, placenta and skeletal muscle. Moderate 
expression was found in pancreas, prostate, testis, ovary, lung, spleen, and 
colon, and low expression was found in thymus and small intestine.  In addition, 
a 4.2-kb transcript was found in low abundance in ovary, peripheral blood 
leukocytes, and liver, as well as a 1.7-kb transcript in placenta at low levels [210].  
Northern blot analysis of mouse tissues in the same report showed high levels of 
a 1.8-kb transcript in brain and kidney, and high levels of a 1.3-kb transcript in 
testis and heart [210].  A recent report has confirmed that GABARAPL1 
associates with autophagic vesicles [211] as do other Atg8 family members.  
Moreover, GABARAPL1 has been shown in cultured cells, to cooperate with 
BNIP3L/Nix in selective autophagic disposal of damaged mitochondria [199]. 
 
6.4 GABARAP-like 2 
 
GABARAP-like 2 (GABARAPL2) was first identified as a Golgi-associated 
ATPase enhancer of 16 kDa (GATE-16) interacting with N-ethylmaleimide 
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sensitive fusion protein (NSF) and Golgi v-snare [212].  Later, GABARAPL2 was 
shown to be present in autophagosomes induced by starvation [207].  
 
6.5 Atg8 family interacting motif and the docking site 
 
Several analyses have suggested that the interaction between cargo receptors 
and Atg8 family proteins is mediated by specific and conserved sequences on 
the cargo receptors, a so-called Atg8 family interacting motif (AIM)  [213] or LC3 
interacting region (LIR) [167].  The core sequence of an typical AIM is WxxL-like 
sequence [213] (Figure 8).  Based on current knowledge of those reported Atg8 
family interacting proteins, the consensus sequence of AIM could be refined as 
X-3-X-2-X-1-W/F/Y-X1-X2-L/I/V, where acidic residues usually occupy X1 and/or X2 
and at least one of X-3-X-2-X-1 positions [194].   
 
 
Figure 8.  Sequence alignment of reported AIMs and their interacting Atg8 
family proteins [213]. 
p62, Sequestosome protein-1 (SQSTM1); NBR1, Next to BRCA1 gene 1 protein; 
CRT, calreticulin; CHC, clathrin heavy chain; PSSM, sequence position-specific 
scoring matrix determined by phage display screening. 
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A conserved surface, LIR docking site (LDS) on Atg8-family proteins is used for 
interaction with the hydrophobic AIM.  The LDS on Atg8-family proteins consists 
of two hydrophobic pockets, W-site and L-site, formed by the side-chains of two 
groups of hydrophobic residues [214].  The aromatic residue is required for the 
W-site of LDS and the large hydrophobic residue is required for the L-site [194].  
Mutations in LDS or AIM impair the binding of Atg8-family proteins to AIM-
containing cargo receptors and hence disrupt the cargo transport [167, 198, 199, 
214].   
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RESEARCH OBJECTIVE 
 
Since the first report on the cloning of human Stbd1 in 1998, few studies have 
addressed this novel protein except for a couple of bioinformatic analyses listing 
it as one of the CBM20-containing proteins.  Through different yeast two-hybrid 
screens carried out previously in our laboratory (Skurat, A.V. unpublished data), 
Stbd1 showed up as potentially interacting with several proteins involved in 
glycogen metabolism, e.g. GS, GBE and DBE/AGL.  When a truncated form of 
human Stbd1 was used as bait for a yeast two-hybrid screen, the identified 
targets included two autophagy related proteins.  From this background, we 
sought to understand the role of Stbd1 in the context of glycogen metabolism and 
whether it had any relevance to an autophagy-like pathway for lysosomal 
degradation of glycogen.  
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EXPERIMENTAL PROCEDURES 
 
1. Yeast two hybrid screen 
 
The yeast Saccharomyces cerevisiae strain PJ69-4A transformed with the 
previously constructed bait plasmid pGBDU-GenethC containing the cDNA that 
encodes 179-358 of human Stbd1 was subsequently transformed with a human 
skeletal muscle cDNA library HL4010 (Clontech) in pGAD vector.  Positive 
colonies were selected from synthetic medium lacking uracil, leucine, and 
adenine (Sc-Ura-Leu-Ade) and re-plated on synthetic medium without uracil, 
leucine, and histidine (Sc-Ura-Leu-His) but with 5 mM 3-amino-1,2,4-triazole (3-
AT).  The library plasmids selected from the second screen were rescued in E. 
coli RRI cells via electroporation and screened by M9 medium deficient in leucine.  
The rescued plasmids were analyzed by yeast two-hybrid tests and DNA 
sequencing.  The purified pGAD plasmids were transformed back into yeast with 
pGBD plasmids and quantitative assay of β-galactosidase activity was carried out 
to evaluate interactions [215].  (Figure 9) 
 
1.1 Yeast transformation (lithium-acetate method) 
 
Five ml of overnight culture of yeast was aliquotted and pelleted down in 1.5 ml 
microcentrifugation tubes at 18,000 g (Beckman counter microfuge 22R 
centriguge) for 5s.  After removal of supernatant, 240 μl of 50% (w/v) PEG3350, 
36 μl of 1 M LiAc, pH7.5, 5 μl of 10 mg/ml single strand carrier DNA (ssDNA), 
0.1-5 μg of plasmid DNA and 65 μl of sterile H2O were added to the pellet and 
vortexed for 1min to mix well.  The mixture was then incubated at 30°C for 5min 
followed by 20min incubation at 42°C.  After 10s centrifugation at 18,000 g, the 
pellet was resuspended in 0.2 ml of sterile H2O and plated on selective plates.  
The plates were incubated at 30°C.  For cDNA library transformation, yeast cells 
were harvested by centrifugation at 18,000 g for 5min when cell titers reached 
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2x107cells/ml and washed with sterile H2O.  To the pellet, 10 volumes of the 
above reagents and DNAs were added.   
 
1.2 Isolation of yeast DNA 
 
Ten ml of overnight yeast culture was centrifuged and the pellet was 
resuspended in 0.2 ml of yeast lysis solution containing 2% Triton X-100, 1% 
SDS, 100 mM NaCl, 100 mM Tris-HCl, pH8.0, 1 mM EDTA, 0.2 ml of phenol: 
chloroform (CHCl3): Isoamyl alcohol (IAA) (25:24:1) and 0.3g of acid-washed 
glass beads (425-600 μm).  The mixture was vortexed for 2 min followed by 
centrifugation at 18,000 g for 5 min. Supernatant, 180 μl, was transferred to a 
clean microcentrifugation tube, and 20 μl of 3M NaAc and 0.5 ml of cold ethanol 
were added.  After 10 min centrifugation at 18,000 g, the pellet was washed with 
0.2 ml of 70% ethanol, dried by vacuum for 5 min and resuspended in about 50 
μl of TE buffer containing 10 mM Tris and 1 mM EDTA.  
 
1.3 Rescue of plasmid in E. coli RRI cells by electroporation 
 
Thawed on ice, 40 μl of E. coli RRI competent cells were added 2 μl of DNA 
isolated from yeast.  The mixture was transferred to an electroporation cuvette 
with 0.1 cm electrode gap (BioRad) and the voltage was set to 2.5 kV.  After 
exposure to high voltage, 1 ml of LB was added quickly.  The mixture was 
transferred to a clean microcentrifugation tube and incubated in shaker at 37°C, 
200 rpm for 1h. The pellet was resuspended in 0.8-1 ml of 10% glycerol and 100-
150 μl of the resuspended cells were plated on M9 medium lacking leucine (M9-
Sc-Leu) with 0.1 mg/ml ampicillin, 1 mM thiamine-HCl and 0.01 mg/ml proline.  
The plates were incubated at 37°C for at least 16h.  
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Figure 9.  Yeast two hybrid screen. 
(A) Principle of the system.  BD: DNA-binding domain; AD: transcriptional 
activation domain.  (B) Flow chart of the system. 
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1.4 E-galactosidase activity assay 
 
Individual yeast colonies were inoculated into appropriated synthetic medium 
containing glucose and incubated in a shaker at 200rpm at 30°C till OD600 =~1.  
On ice, 0.1 ml of overnight culture or H2O as blank was mixed in 1.5 ml 
microcentrifugation tube with 0.7 ml of Z-buffer (60 mM Na2HPO4.7H2O, 40 mM 
NaH2PO4.H2O, 10 mM KCl, 1 mM MgSO4.7H2O, pH7.0) with 50 mM of 2-
mercaptoethanol, 50 μl of chloroform (CHCl3) and 50 μl of 0.1% SDS.  The 
mixture was vortexed for 2min and 0.16 ml of freshly made O-nitrophenyl-β-D-
galactopyranoside (ONPG) solution containing 4mg/ml ONPG, 60 mM 
Na2HPO4.7H2O, 40 mM NaH2PO4.H2O, pH7.0 was added.  After 60min 
incubation at 30°C, the reaction was quenched by adding 0.4 ml of 1M Na2CO3.  
Cell debris were pellet down after 10min of centrifugation at the 18,000 g and 1 
ml of supernatant was transferred into clean cuvette to read OD420.  The linear 
range is around 0.2-0.8.  Meanwhile, 0.1 ml of overnight yeast culture kept on ice 
was mixed with 0.9 ml of H2O to read OD600, using H2O as blank.  The E-
galactosidase activity was calculated as following: E-galactosidase activity 
units=1000 x OD420 / (t x V x OD600) in which t= incubation time (min), V= volume 
(ml) of culture added to Z-buffer.    
 
2. Plasmid construction 
 
The cDNA corresponding to the coding region of human Stbd1 (1076bp) was 
amplified by polymerase chain reaction (PCR) (Initial denaturation at 95°C for 5 
min; 30 cycles of denaturation at 94°C for 1 min, annealing at 65°C for 1 min, 
extension at 72°C for 2 min; and the last extension at 72°C for 10 min).  The 
primers (forward: 5’-G↓GA TCC ATG GGC GCC GTC TGG TCC GCC C-3’ and 
reverse: 5’-G↓AA TTC TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA GTG 
AAT CCC CCA CCA TGC GTG A-3’) were designed to introduce restriction sites 
BamHI and EcoRI as underlined, and the sequence of the HA tag (YPYDVPDYA) 
expressed at the C-terminus of the protein as curved underlined.  The TA cloning 
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kit was used to insert the amplified DNA fragment into pCR2.1 vector.  When 
cDNA sequences of human Stbd1 coding region were verified by the DNA 
sequencing Core Facility at the Indiana University School of Medicine, the cDNA 
was subcloned to pcDNA3 vector for mammalian expression (Figure 10), and 
pET28a/pET32a and pGEX vectors for E. coli expression, via restriction digestion 
at 37°C and ligation at 16°C.  The cDNA corresponding to the coding region of 
mouse Stbd1 (1016bp) was also amplified and cloned with the same strategy 
(Figure 11). The primers are forward: 5’-G↓GA TCC ATG GGC GCC GTC TGG 
TCA GCC C-3’ and reverse: 5’- G↓AA TTC TCA AGC GTA ATC TGG AAC ATC 
GTA TGG GTA GTG AAT CCC CCA CCA CCC ATG A-3’.  
 
The cloning of GABARAP and GABARAPL1 followed the similar procedure 
(Figure 12).  The primers for GABARAP (forward: GC↓G GCC GCT ATG AAG 
TTC GTG TAC AAA and reverse:  T↓CT AGA TCA CAG ACC GTA GAC ACT 
TTC GTC AC) were designed to introduce restriction sites NotI and XbaI as 
underlined.  The primers for GABARAPL1 (forward: 5’-G↓ AAT TCA ATG AAG 
TTC CAG TAC AAG GAG GAC CAT-3’ and reverse:  5’-T↓CT AGA TCA TTT 
CCC ATA GAC ACT CTC ATC ACT G-3’) were designed to introduce restriction 
sites EcoRI and XbaI as underlined.  The cDNA of GABARAP and GABARAPL1 
coding region were subcloned by restriction digestion and ligation with the 
pFlagCMV vector for mammalian expression, and pET32a and pGEX vectors for 
E. coli expression.   
 
3. Ligation, transformation and plasmid preparation 
 
PCR product and pCR2.1 vector (Invitrogen), or DNA fragment and vector 
plasmid yielded by restriction digestion were mixed with deionized sterile H2O, 
ligation buffer and T4 ligase (New England Biolabs) and incubated at 16°C for 
16-20h. 
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Ligation product, 5 μl or 50ng of plasmid was added to 100 μl competent cell of E. 
coli DH5α thawed on ice.  The mixture was set on ice for 15min followed by heat 
shock at 42°C for 45s.  LB, 500 μl was added and the mixture was incubated at 
37°C, shaking at 200 rpm for 1h.  The culture was pelleted down by quick 
centrifugation and 300 μl of the supernatant was removed.  The pellet was 
resuspended in the rest supernatant and 50 μl or 100 μl of the suspension was 
plated on LB plates with proper antibiotics.  The plates were incubated at 37°C 
for at least 16h. 
 
Plasmids were prepared by BioRad miniprep kit following factory instruction. 
 
4. Mutagenesis 
 
Mammalian expression vectors containing HA tagged hStbd1 (hStbd1-HA) and 
different truncation mutants thereof (ΔN24-HA, ΔN90-HA, ΔC96-HA) for 
mammalian expression were made by PCR amplification of a human cDNA with 
addition of an HA tag at the C-terminus.  The products were subcloned into 
BamHI/EcoRI sites of the pCDNA3 vector (Figure 10 and 14).  Plasmids with 
point mutations or short deletions in the carbohydrate binding domain (W293G-
HA and W293L-HA) and the Atg8-family interacting motif (Δ198-222-HA, W203A-
HA, V206A-HA, W212A-HA, V215A, W203A+V206A-HA, W212A+V215A-HA) 
were constructed by site-directed mutation using pCDNA3-hStbd1-HA as 
template (Figure 13 and 14).  The primers containing the mutated sequences 
were designed using the online service of PrimerX 
(http://www.bioinformatics.org/primerx/) and were synthesized by Invitrogen.  The 
Pfu Turbo DNA polymerase (Stratagene) was used for the PCR.  PCR cycling 
condition: initial denauration was at 95°C for 5 min, denaruation was at 95°C for 
1 min, 20 cycles including denaturation at 95°C for 1 min, annealing at 60°C for 1 
min and extension at 68°C for 12 min.   
The PCR product was digested with Dpn I (New England Biolabs) at 37°C for 2-
3h to remove the parental DNA.  The PCR product was transfected into 
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competent cells to generate pcDNA3-W293G-HA and pcDNA3-W293L-HA,.  His-
tagged or GST-fusion hStbd1 (human Stbd1) and mStbd1 (mouse Stbd1) vectors 
for bacterial expression were constructed by subcloning into pET28a or pGEX 
vectors.  
  
Sequences of all constructs were verified by the DNA sequencing Core Facility at 
the Indiana University School of Medicine.  
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Figure 13.  Site-directed mutegenesis. 
Point mutations of conserved trypsine residue within CBM20 into glycine or 
leucine, W293G and W293L).  Deletion and single or double point mutations of 
potential ATG8 family interacting motif (AIM), Δ198-222, W203A, V206A, W212A, 
V215A, W203A+V206A and W212A+V215A).  
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Figure 14.  Schematic architecture of human Stbd1 and mutants.   
(A) Full length human Stbd1; Deletion of the N-terminal hydrophobic segment 
(ΔN24-HA); Deletion of the N-terminal hydrophobic segment and the putative 
leucine zipper (ΔN90-HA); Deletion of the C-terminal carbohydrate binding 
domain (ΔC96-HA); Mutation of conserved Trp of CBM20 domain to Gly 
(W293G); Mutation of conserved Trp of CBM20 domain to Leu (W293L); Deletion 
of region including putative Atg8 family interacting motif (AIM) /LC3 interacting 
region (LIR); Mutation of conserved Trp or Val into Ala (W203A, V206A) within 
the first potential AIM; Mutation of conserved Trp or Val into Ala (W212A, V215A) 
within the second potential AIM; Double mutation of both conserved Trp and Val 
into Ala (W203A+V206A) within the first potential AIM; Double mutation of both 
conserved Trp and Val into Ala (W212A+V215A) within the second potential AIM. 
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5. Expression and purification of recombinant proteins 
 
E. coli BL21 (DE3) competent cells transformed with pET28a-hStbd1, pET28a-
mStbd1 and pGEX-mStbd1 vectors were grown at 37°C till the OD600 reached 
0.4.  Protein expression was induced by 0.4 mM isopropyl-β-d-thiogalactoside 
(IPTG) at 18°C overnight.  The His-tagged hStbd1 and mStbd1 were purified by 
Ni2+–NTA agarose chromatography (Qiagen).  The proteins were eluted stepwise 
with 40 mM to 200 mM imidazole.  hStbd1 and mStbd1 were eluted primarily in 
fractions with 100 and 200 mM imidazole.  The eluted fractions were dialyzed 
against buffer containing 50 mM Tris HCl, pH 7.5, 150 mM NaCl and 5% 2-
mercaptoethanol and stored at −80°C with 15% glycerol.  The His-tagged 
mStbd1 was dialyzed against PBS, pH 7.4 and to Affi-Gel 15 for antibody affinity 
purification.  The GST-fusion mStbd1 for antibody generation was purified using 
glutathione Agarose (Sigma). The recombinant protein was eluted with 10 mM 
glutathione and dialyzed against phosphate-buffered saline (PBS). 
 
6. Glycogen purification and polysaccharide binding assay 
 
Glycogen was purified from mouse muscle as previously described [216].  Briefly, 
tissues were boiled in 30% KOH and lipids were removed by the 
methanol/chloroform extraction.  Glycogen precipitated in cold ethanol and 
redissoved in H2O was treated with 10% trichloroacetic acid (TCA).  After 
centrifugation, glycogen recovered from the supernatant by ethanol precipitation 
was subjected to extensive dialysis. 
   
Recombinant hStbd1 was diluted in 50 mM Tris HCl pH7.5, 150 mM NaCl, 0.1% 
2-mercaptoethanol, 0.1% TritonX-100 and subjected to 10,000 g centrifugation at 
4°C for 20 min.  The supernatant was mixed with the supernatant of 
glycogen/amylopectin centrifuged under same conditions.  The final 
concentration of protein was 2.5 μg/ml and glycogen/amylopectin was 0.25 
mg/ml.   Stbd1 without polysaccharide was used as negative control.  The 
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samples were mixed well, incubated at 4°C for 1h, and then subjected to 
ultracentrifugation at 100,000 g at 4°C for 90 min.  The pellets were resuspended 
by sonication.  The supernatant and pellets were subjected to western blotting for 
hStbd1. 
 
7. Antibodies 
 
Rabbit polycolonal antibodies were generated against GST-mStbd1 by Cocalico 
Biologicals.  The antibody was Affinity purified by Affi-Gel 15 (Bio-Rad) coupled 
with His-tagged mStbd.  Rabbit polycolonal anti-HA epitope tag antibodies were 
from Rockland (Gilbertsville).  Mouse monoclonal anti-HA epitope tag antibodies 
were from Covance (Emeryville).  Mouse monoclonal anti-Flag M2 antibodies 
were from Sigma.  Rabbit monoclonal Syntaxin 6 and glycogen synthase 
antibodies were from Cell signaling.  Mouse monoclonal glycogen synthase 
antibodies were from Invitrogen.  Rabbit monoclonal GS antibodies were from 
Cell signaling.  Rabbit polyclonal anti-hStbd1 antibodies (anti-GENX-3414) were 
from Protein Tech Group.  Rabbit polycolonal GABARAPL1antibodies were from 
Protein Tech Group.  Mouse monoclonal LC3 antibodies were from NanoTools.   
 
8. Cell culture and transfections 
 
COS M9 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, 
Mediatech or Sigma) with 25 mM glucose and 10% fetal bovine serum 
(FBS)(Atalanta Biologicals, Lawrenceville).  Transfections were performed with 
Fugene 6 (Roche) following the manufacturer’s instructions.  Six-well plate or 35 
mm plates were used for immunoblotting or immunoprecipitation, and for 
immunofluorescence microscopy, 12-well plates were used with cells growing on 
coverslids at the bottom of each well.  Glucose starved COS M9 cells were 
incubated in DMEM without glucose and supplemented with sodium pyruvate 
(Invitrogen) and 10% FBS.  The normal "fed" condition had 25 mM D-glucose 
(Sigma). 
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Rat1Neo5 and Rat1WT4 cells [217]  were grown in DMEM with 25 mM glucose 
and supplemented with 10% fetal bovine serum and 0.25 mg/ml geneticin.  
Rat1WT4 is a stably transfected cell line over-expressing wild type rabbit muscle 
glycogen synthase.  Rat1Neo5 cells are a control line transfected with vector.  
FL83B cells (ATCC) were grown in F-12K medium (ATCC) and supplemented 
with 10% FBS.  C2C12, Hepa1c1c, HepG2, HII4EC3 mouse embryonic 
fibroblasts (MEF) were grown in DMEM with 25 mM glucose with 10% FBS.  
C2C12 cells were differentiated in DMEM with 25 mM glucose and supplemented 
with 1% bovine calf serum.  All cells were incubated at 37°C with 5% CO2. 
 
9. Preparation of tissue and cell extracts and immunoblotting  
 
MGSKO [95] and LGSKO mice [93] have been described previously.  They carry 
disruptions of the glycogen synthase genes Gys1 or Gys2 respectively. The 
exercise protocol followed a previous study [218].  Mice were sacrificed by 
cervical dislocation.  Tissues were rapidly frozen in liquid nitrogen and stored at 
−80°C.  Frozen tissues were powdered and homogenized in buffer containing 50 
mM Tris HCl (pH 7.8), 10 mM EDTA, 2 mM EGTA, 0.1 mM N-p-tosyl-l-lysine 
chloromethyl ketone (TLCK), 2 mM benzamidine, 0.5 mM phenylmethylsulfonyl 
fluoride (PMSF), 50 mM 2-mercaptoethanol and 10 μg/ml of leupeptin, with or 
without 0.5% Triton-X.  Tissue homogenates were used for Western blotting 
analysis.  For analysis of mStbd1 and glycogen fractionation, tissue 
homogenates were first subjected to low speed centrifugation 10,000 g at 4°C for 
10 min to generate a low speed pellet (LSP) and the supernatant (LSS) was 
subjected to further centrifugation.  Centrifugation at 100,000 g at 4°C for 90 min, 
generated a high speed supernatant (HSS) and glycogen was collected in the 
high speed pellet fraction (HSP).  The HSP was resuspended in the starting 
volume of homogenization buffer.  All fractions were analyzed by Western 
blotting with anti-mStbd1 antibodies.   
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Cultured cells were lysed in buffer containing 50 mM Tris HCl, 100 mM NaCl, pH 
7.5, 0.5% TritonX-100, 1 mM PMSF, 0.1 mM TLCK, 1 mM benzamidine, 1 μg/ml 
of aprotinin, pepstatin and leupetin. The cell lysates were centrifuged at 10,000 g 
for 15 min at 4°C to pellet insoluble materials.  
  
Protein concentration was determined by the Bradford method using BSA as 
standard [219].  Samples were subjected to 10% SDS-PAGE.  Proteins were 
transferred to nitrocellulose membranes, blocked in Tris buffered saline (TBS) 
with 5% milk and incubated with antibodies diluted in TBS with 2% milk, followed 
by incubation with horseradish peroxidase (HRP)-conjugated secondary 
antibodies diluted in TBS with 2% milk and development by ECL western blotting 
substrate (Thermo Scientific).  
 
10. Co-immunoprecipitation  
 
COSM9 cells co-expressing C-terminal HA-tagged hStbd1and N-terminal Flag-
tagged proteins like GABARAP, GABARAPL1 or laforin were lysed and 
centrifuged at 8,000 g for 15 min at 4°C. EZview red anti-Flag gel or EZview red 
anti-HA affinity gel (Sigma) was equilibrated with lysis buffer before use. The 
supernatant from cell lysates was mixed with affinity gel and incubated at 4°C 
overnight. The samples were centrifuged at 8,000 g for 30s to pellet the agarose. 
The agarose was washed by lysis buffer three times and loading buffer was 
added for SDS-PAGE and immunoblotting. 
 
11. Immunofluorescence staining and microscopy 
 
Cells were grown on glass coverslips 24 h or 48 h before fixation.  Cells were 
fixed in PBS with 4% paraformaldehyde (PFA) for 3 x10min with 2min PBS wash 
in between, and then quenched and permeabilized in PBS with 100 mM glycine 
and 0.2% TritonX-100.  Nonspecific binding sites were blocked with 5% bovine 
serum albumin (BSA) (Sigma) in PBS. The cells were incubated with primary 
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antibodies in PBS with 2% BSA at room temperature for 1-2h.  Antibody dilutions 
were as follows: anti-mStbd1, 1:200; anti-HA, 1:1000; anti-FLAG, 1:1000; anti-
GABARAPL1, 1:100; anti-LC3, 1:100; and anti-glycogen synthase, 1:200. Cells 
were then washed in PBS with 2% BSA and developed with secondary 
antibodies (1:400, Invitrogen), conjugated with either Texas Red or Alexa488 
fluorophores.  Nuclei were visualized by staining with 1 μg/ml Hoechst 
(Invitrogen).  The specimens were washed in PBS and then milliQ H2O before 
mounting.  The slides were viewed on a Zeiss Axio Observer Z1 microscope with 
a Plan Apochromat ×63 oil immersion objective (Zeiss).  Images were processed 
with Zeiss Axiovision 4.7.  
 
12. Immunohistochemistry 
 
Fixed mouse liver or muscle sections were deparaffinized by soaking in the order 
into xylene for 3x3min, 100% ethanol for 2x3min, 95% ethanol for 3min and 70% 
ethanol for 3min.  The antigen was retrieved by soaking the specimens into 10 
mM citrate buffer pH6.0 with 0.05% Tween 20 that heated to ~90°C for 20min till 
the temperature dropped to ~50°C and then cooled down to room temperature.  
The specimens were blocked in TBS with 1% BSA and 10% goat normal serum 
and incubated with anti-mStbd1 diluted in TBS with 1% BSA.  Washed by TBS 
with 0.025% TritonX-100, the endogenous peroxidase of specimens was 
inactivated by TBS with 0.3% H2O2.  HRP-conjugated secondary antibody was 
diluted in TBS with 1% BSA.  The staining was developed with 3,3'-
diaminobenzidine (DAB) substrate reagent (BD Biosciences) in the presence of 
HRP.  Harris’ hematoxylin was used for counterstaining to demonstrate nuclei.  
When immunohistochemical staining was followed by PAS staining, the 
counterstaining step was omitted.  The samples were dehydrated before 
mounting by soaking in the order into 70% ethanol for 3min, 95% ethanol for 
3min, 100% ethanol for 2x3min, xylene:ethanol (1:1) for 3min and xylene for 
3x3min.  The stained samples were mounted by xylene substitute mountant 
(Thermo Scientific) and viewed on a Leica DM3000 microscope (Leica). 
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13. Periodic acid-Schiff reagent (PAS) staining and microscopy 
 
Fixed cells were rinsed in ddH2O and oxidized with 0.5% periodic acid for 5 min, 
stained with Schiff reagent for 15 minutes and then counterstained in Harris’ 
hematoxylin for 1 min. Negative controls without periodic acid treatment were 
processed at the same time to ensure staining specificity.  When 
immunofluorescence staining was applied following by PAS staining, the 
counterstaining step was omitted. The method for the combined PAS and 
immunofluorescence staining was adapted from reference [220].  The PAS 
stained samples were viewed on a Leica DM3000 microscope (Leica).  Images 
were processed with Leica Application Suite version 3.5.0.  The samples with 
both PAS and immunofluorescence staining were viewed on a Zeiss Axio 
Observer Z1 microscope and images were processed with Zeiss Axiovision 4.7.  
 
14. Glycogen assay 
 
Sample and standard glycogen was dissolved in 0.3 mg/ml of amyloglucosidase 
in 200 mM NAOAc and digested for 3-4h (or overnight).  Samples were diluted in 
H2O after digestion.  Glycogen was measured in triethanolamine-G6PDH-NADP 
buffer which included 300 mM triethanolamine, 4 mM MgCl2, 2 μg/ml G6PDH, 0.9 
mM β-NADP and 2 mM ATP.  In 300 μl of triethanolamine-G6PDH-NADP buffer, 
10 μl of proper diluted sample or standard glycogen was added and 100 μl of 
mixture was read at OD340 in 50 μl quartz cuvette.  The triethanolamine-G6PDH-
NADP buffer without adding glycogen was used as blank.  Hexokinase was 
diluted in 3.2 M (NH4)2SO4 to 1/2 and 1 μl was added to each 200 μl of sample or 
standard mixture.  After 30 min incubation, samples were read at OD340 again 
and glycogen content (μg glucose/mg protein) can be calculated by standard 
curve or by the following formula (μmol glucose/g protein): 
(Δ OD340/6.22) x 0.31 ml x (0.2 ml/0.01 ml) x dilution factor/protein (g) 
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15. RNA isolation and quantitative PCR  
 
RNA was isolated as previous described [93] using TRIzol reagent (Invitrogen) 
with manufactory instruction.  Primers and probes were designed through 
Universal probe library tool (Roche Applied Science).  Superscript III-RT kit 
(Invitrogen) was used for reverse transcription of isolated RNA.  LightCycler 480 
probes Master reagent and real time PCR system (Roche Applied Science) were 
used for the real time PCRs.  The mRNA content was calculated as previously 
described [221] and the fold change was normalized by reference gene 18S  
 
16. Statistical Analysis 
 
The data are presented as mean ± standard error. Statistical significance was 
determined by unpaired Student's t test and significance was assigned at p < 
0.05.  
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RESULTS  
 
1. Association of Stbd1 with polysaccharides 
 
Because of the presence of the CBM20 domain on Stbd1, our initial goal was to 
analyze the polysaccharides-binding ability of Stbd1 in vitro and in vivo.   
 
1.1 Stbd1 binds glycogen and amylopectin in vitro 
 
For the in vitro binding assay, recombinant human Stbd1 was produced in E. coli 
and purified.  Polysaccharide binding was judged by co-sedimentation of Stbd1 
with either glycogen or amylopectin during ultracentrifugation (100,000 g) (Figure 
15A).  The presence of Stbd1 was visualized by immunoblotting.  Based on this 
assay, Stbd1 is capable of binding to both glycogen and amylopectin, but bound 
more effectively to amylopectin, the predominant polysaccharide of starch which 
differs from glycogen in being less branched and more phosphorylated [222].  
Glycogen also includes small amounts of covalent phosphate whose function is 
poorly understood, at a frequency of 1/ 650 - 1500 glucose residues [15, 216].   
 
As described in the introduction, Lafora disease is a progressive myoclonus 
epilepsy with teenage-onset and usually death within ten years [122].  The 
hallmark of Lafora disease is the accumulation of Lafora bodies, deposits that 
consist of poorly branched glycogen.  Increased phosphorylation of glycogen-like 
polyglucosan in Lafora bodies has been reported [223].  In a mouse model of the 
disease (Epm2a-/- mouse) the gene encoding laforin is disrupted.  Increased 
glycogen phosphorylation has been observed in this mouse line, which led to a 
derangement of glycogen structure with age, accompanied also by reduced 
branching and solubility [15, 216].  Glycogen purified from the muscle of 10-12 
month old Epm2a -/- mice is more phosphorylated and less branched than 
normal mouse muscle glycogen from the wild type (WT) mice.  Stbd1 showed 
increased co-sedimentation with glycogen purified from Epm2a -/- mouse muscle 
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(Figure 15B).  Furthermore, low speed centrifugation (10,000 g) of muscle 
extracts from Epm2a -/- mice essentially separates the normal and aberrant 
glycogen species into supernatant (low speed supernatant, LSS) and pellet (low 
speed pellet, LSP).  The glycogen purified from LSS is relatively normal, while 
the poorly branched, more phosphorylated glycogen is in the LSP [15].  We 
observed that Stbd1 bound more tightly to glycogen purified from the LSP than 
that form LSS fraction (Figure 15B).  Therefore, we conclude that purified Stbd1 
can bind glycogen and interacts preferentially with less branched and/or more 
phosphorylated polysaccharides.    
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Figure 15.  Association of Stbd1 protein with glycogen.   
(A) Recombinant human Stbd1 protein binding to glycogen and amylopectin.  
Rabbit liver glycogen and potato amylopectin (Sigma) were incubated with 
recombinant hStbd1, centrifuged and analyzed by immnonoblotting using anti-
hStbd1 antibodies (anti-GENX-3414).  S, supernatant after centrifugation at 
100,000 g; P, pellet after centrifugation at 100,000g.  The negative control 
contained Stbd1 but without polysaccharide (Buffer).  (B) Recombinant human 
Stbd1 protein binding to glycogen purified from wild type and laforin knockout 
mice.  Total glycogen was purified from mouse skeletal muscle of wild type (WT) 
or laforin knockout (Epm2a -/-) mice.  Muscle extracts from laforin knockout mice 
was additionally fractionated by low speed centrifugation (10,000 g) to separate 
supernatant and pellet.  Glycogen was purified from this supernatant (Sup) and 
pellet (Pellet).  Purified mouse glycogen (WT total, Epm2a -/- total, Epm2a -/- 
Sup and Epm2a -/- Pellet) was incubated with recombinant hStbd1, centrifuged 
at 100,000 g and the supernatant (S) and pellet (P) fractions analyzed by 
immunoblotting. Stbd1 without added glycogen (Buffer) was the negative control. 
(C) Fractionation of Stbd1 by centrifugation of wild type mouse muscle extracts in 
the presence or absence of Triton X-100.  Fractions were analyzed by 
immunoblotting using anti-mStbd1 antibodies, as described under experimental 
procedures.  LSS, supernatant after centrifugation at 8,000 g centrifugation; LSP, 
pellet after centrifugation at 8,000 g; HSS, supernatant after centrifugation at 
100,000 g; HSP, pellet after centrifugation at 100,000 g.  The panels shown were 
cropped from a single autoradiogram of a single membrane.   
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1.2 Stbd1 interacts with glycogen in muscle extract 
 
Glycogen in muscle extracts can be fractionated by centrifugation, typically by 
first removing gross cellular debris, including contractile proteins and associated 
structures, with a low speed centrifugation (10,000 g) followed by 
ultracentrifugation (100,000 g) of the supernatant to sediment the glycogen 
particles.  In our experiments, about half of the Stbd1 was recovered in the LSP, 
possibly because of the association with membranous components since by 
adding a non-ionic detergent Triton X-100 in the homogenization buffer, a greater 
portion of Stbd1 was present in the LSS fraction (Figure 15C).  After high speed 
centrifugation of the low speed supernatant in the absence of Triton X-100, 
almost all of the soluble Stbd1 was recovered in the high speed pellet (HSP) 
fraction (Figure 15C).  When the detergent was present, a substantial amount of 
Stbd1 was still recovered in the HSP although some was left in the high speed 
supernatant (HSS).  Hence, the results indicate that a significant fraction of the 
Stbd1 in a muscle extract cofractionates with glycogen because of direct binding 
to the polysaccharide.   
 
1.3 Endogenous Stbd1 distribution in mouse tissues 
 
The commercially available anti-GENX3414 antibody against human Stbd1 
(hStbd1) is not able to recognize mouse Stbd1 (mStbd1), probably because the 
protein sequences of mouse and rat Stbd1 have only 60% identity with that of the 
human protein.  We raised antibodies against recombinant GST-fusion mStbd1 
and affinity purified it by binding to immobilized His-tagged mStbd1.  Using these 
antibodies, a single protein species of ~36 kDa was identified in extracts of most 
mouse tissues tested (Figure 16), including liver, skeletal muscle, adipose tissue, 
lung, heart and spleen.  Liver and muscle, the two major glycogen depositories 
(Table 2), showed particularly prominent signals of Stbd1 by immunoblotting, 
consistent with the earlier report [161].  Overexposure of the autoradiogram 
revealed trace signals in brain, kidney and pancreas.   
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Figure 16.  Endogenous distribution of Stbd1 protein in mouse tissues. 
Stbd1 protein levels in mouse tissues as judged by immunoblotting with anti-
mStbd1 antibodies.  M, skeletal muscle; Li, liver; A, adipose; B, brain; K, kidney; 
Lu, lung; H, heart; S, spleen; P, pancreas; +, extract of COS M9 cells over-
expressing mStbd1 (running larger because of C-terminal HA-tag).  Loadings 
were 10 μg total protein.  
 
Tissue Glycogen (μmol glucose / g tissue) 
Skeletal muscle 17.3 
Liver 384.6 
Adipose tissue 0.2 
Brain 2.3 
Kidney 0.3 
Lung 1.8 
Heart 1.9 
Spleen 1.4 
Pancreas 0.1 
Irimia, J.M. unpublished data. 
Table 2.  Glycogen content in different mouse tissues. 
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1.4 Correlation of Stbd1 with glycogen levels in different genetically 
modified mice 
 
Muscle glycogen synthase knockout (MGSKO) mice [95] are disrupted in the 
Gys1 gene which encodes the isoform of GS expressed in skeletal muscle and 
most tissues that produce glycogen except liver.  Glycogen is undetectable in 
cardiac and skeletal muscle from survived knockout mice.  Immunoblotting of 
muscle extracts from MGSKO mice had virtually imperceptible Stbd1 protein 
compared with controls (Figure 17A).  Muscle glycogen can also be acutely 
reduced by 90% of the starting level when mice were exercised to exhaustion on 
a treadmill [218].  Stbd1 protein levels were not changed by this exercise 
regimen as judged by immunoblotting of muscle extracts from wild type mice 
(Figure 17B).   
 
Liver glycogen synthase knockout (LGSKO) mice [93] have a disruption of the 
Gys2 gene in the liver, which encodes the liver isoform GS.  The liver glycogen 
level in the fed state of the knockout mice is decreased to 5% of the wild type 
level.  The Stbd1 protein level was reduced by 40% in extracts of livers from fed 
LGSKO mice compared to control mice (Figure 17C).  In addition, the reduction 
of Stbd1 was seen by immunohistochemical staining of liver sections, in which a 
visible difference was observed between LGSKO and control (Figure 17D).  After 
overnight fasting, approximately 95% of liver glycogen is degraded in wild type 
mice, giving a glycogen content comparable to that of fed LGSKO liver [93].  
Stbd1 protein levels did not show significant reduction in either WT or LGSKO 
mice in the fasted state (Figure 17C).  
 
From the data with MGSKO and LGSKO mice, we observed that absence or 
reduction of glycogen over the long term correlates with decreased Stbd1 protein, 
whereas short term decreases in either liver or muscle glycogen in wild type mice 
have no significant effects.  The results with the genetically modified mouse lines 
argue for a genetic link between glycogen and Stbd1.  In addition, a strong trend 
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to elevate Stbd1 mRNA level was observed in the muscle of non-exercised 
MGSKO mice compared to control WT mice (p=0.0587), while the mRNA level of 
Stbd1 in the fed LGSKO mouse liver was not significantly changed (Figure 18).  
Summarily, in the muscle of MGSKO mice where no baseline glycogen content 
could stabilize Stbd1 protein, the protein is absent.  The permanent depletion of 
glycogen may also serve as a feedback signal to Stbd1 expression, which leads 
to a tendency of increasing mRNA level.  In the LGSKO mice, with 95% reduction 
of liver glycogen, the Stbd1 protein level was only lowered by 40% without 
significant change in mRNA level.  These observations indicate that Stbd1 
protein could have relatively long half-life and can be stabilized by glycogen.   
 
 
 
Figure 17.  Correlation of Stbd1 protein level with genetic modified 
glycogen level in mice. 
(A) Stbd1 protein level in skeletal muscle from muscle glycogen synthase 
knockout (MGSKO) mice, with the Gys1 gene disrupted, and control WT 
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littermates.  GS, glycogen synthase; GAPDH, glyceraldehyde-3-phosphate 
dehydrogenase, the loading control.  (B) Stbd1 levels in exercised versus non-
exercised wild type mice.  A representative Western blot is shown as well as 
quantitation in the lower bar graph. Numbers within the bars indicate the number 
of mice analyzed.  (C) Representative immunoblots for Stbd1 in livers of fed 
floxed conditional (HoCD) control mice and liver glycogen synthase knockout 
(LGSKO) mice, with Gys2 gene disrupted.  Quantitation of Stbd1 levels in control 
or LGSKO mice under fed or fasted conditions is shown in the bar graph below.  
* p<0.05 with respect to HoCD.  (D) Stbd1 visualized in liver sections of fed 
LGSKO and control mice (HoCD) by immunohistochemical staining.  
 
 
 
Figure 18.  mRNA level of Stbd1 in liver and muscle.   
(A) mRNA level in skeletal muscle of non-exercised MGSKO mice and control 
WT littermates (p=0.0587 with respect to WT).  (B) mRNA level in liver of fed 
LGSKO mice and control WT littermates (p=0.4202 with respect to HoCD).  
mRNA content was measured by real time PCR and normalized by reference 
gene 18 S.  Numbers within the bars indicate the number of mice analyzed. 
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2. Structure-function analysis of Stbd1 
 
Since Stbd1 has been observed binding to polysaccharides in vitro and in vivo 
with a preference for poorly branched polysaccharides, and correlating with 
genetic depletion of glycogen in mouse models, we focused on the structure-
function analysis of Stbd1 for further study.   
 
2.1 Sequence analysis 
 
The architecture of Stbd1 indicates an N-terminal hydrophobic segment of 24 
amino acids, a putative leucine-zipper domain with three heptad repeats, and a 
CBM20 domain at the C-terminus (Figure 14) that is conserved from prokaryotes 
to higher eukaryotes.  Human Stbd1 (hStbd1) is 358 residues long with 20 and 
25 more amino acids than the mouse (mStbd1) and rat proteins respectively.  
Mouse and rat Stbd1 share 64-65% identity to the human protein and 89% to 
each other.  To date, orthologs of Stbd1 or predicted Stbd1-like proteins have 
been identified from zebrafish, chicken to a number of mammals.  The number of 
entries is probably still expanding since when we first analyzed databases three 
years ago, Stbd1 only showed up in mammals from bioinformatic analysis.  The 
hydrophobic N-terminus and C-terminal CBM20 domains of Stbd1 show a very 
high degree of conservation (Figure 19).  The yeast two hybrid screen using 
Stbd1 lacking the first 171 residues as bait, picked four Stbd1 clones of different 
lengths from a human skeletal muscle cDNA library (Figure 20).  One clone was 
the same as the bait.  The longest clone was only missing the first six amino 
acids.  The two shortest clones were the same, containing a little more than the 
CBM20 domain.  Therefore, it is likely that Stbd1 can oligomerize by interactions 
between the CBM20 domains.  The putative leucine-zipper domain seems not 
related to this oligomerization.   
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Figure 19.  Sequence alignment of mammalian Stbd1.   
Sequences were aligned with the Clustal algorithm, with darker shading denoting 
greater degrees of conservation among species.  The orange box indicates the 
highly conserved hydrophobic N-terminal twenty four residues.  The purple box 
encloses the putative leucine zipper motif.  The red box encloses the conserved 
CBM20 domain.  The green box encloses the region includes two potential Atg8 
familiy interacting motif (AIM) /LC3 interacting region (LIR) motif.  The pink box 
encloses tow potential AIMs.  The pink box with dashed lines encloses a putative 
AIMs that is excluded due to low sequence conservation. 
 
 
 
 
Figure 20.  Stbd1 clones of different lengths identified by C-terminal half of 
Stbd1 in yeast two hybrid screen.   
The longest clone is only missing the first six amino acids.  One clone without the 
first 171 amino acids is the same as the bait.  The two shortest clones are the 
same, containing 10 more amino acids than the CBM20 domain. 
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2.2 Detection of endogenous Stbd1 in cell lines 
 
In several cultured cell lines including mouse C2C12, Hepa1c1c, embryonic 
fibroblasts (MEFs) and FL83B cells, as well as rat H4IIEC3 and Rat1 cells, we 
detected endogenous Stbd1 by immunoblotting with the anti-mStbd1 (Figure 21A) 
but not in human HepG2 or simian COS M9 cells, which again may be explained 
by relatively low sequence identities of Stbd1 in rodents and primates.  
 
In either the mouse liver cell line FL83B [224] or a Rat1 fibroblast cell line, 
Rat1Neo5 [217], endogenous Stbd1 was detected by immunofluorescence, to 
appear predominantly concentrated at perinuclear structures, with diameter up to 
~0.5 μm (Figure 21B).  These structures partly coincide with the presence of an 
ER marker, residues HDEL, detected by anti-HDEL (Figure 22).  Endogenous 
Stbd1 also exists within areas with the densest microtubular network (Figure 22).  
 
Figure 21.  Endogenous Stbd1 in mouse and rat cells.   
(A) Presence of Stbd1 protein in mouse and rat cell lines, as described in the text. 
+, COS M9 cells over-expressing mStbd1.  (B) FL83B (left panel) and RatNeo5 
(right panel) cells were immunostained with anti-mStbd1 antibodies (red) to 
detect endogenous Stbd1.   
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Figure 22.  Subcellular localization of endogenous Stbd1 with respect to 
organelle markers in FL83B and Rat1Neo5 cells. 
(A) FL83B cells were immunostained with antibodies directed towards mStbd1 
(middle panels) and antibodies towards HDEL, as an endoplasmic reticulum 
marker (lower left panel), or against β-tubulin as a microtubule marker (lower 
right panel).  The upper panels show merges of the images, with Stbd1 (red) and 
the corresponding organelle marker (green), with nuclei stained with Hoechst 
(blue).  (B) Rat1Neo5 cells were immunostained with antibodies directed towards 
mStbd1 (middle panels) and antibodies towards, HDEL, as an endoplasmic 
reticulum marker (lower left panel), or against β-tubulin as a microtubule marker 
(lower right panel).  The upper panels show merges of the images, with Stbd1 
(red) and the corresponding organelle marker (green), with nuclei stained with 
Hoechst (blue).  The scale bars are 20 μm.  
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2.3 Structure and function analysis by study of hStbd1-HA and mutants 
 
When the HA-tagged full length human Stbd1 (hStbd1-HA) was transiently 
expressed in COS M9 cells, the protein was located in perinuclear structures with 
diameters up to several μm (Figure 23A, 24).  Both syntaxin 6, a trans-Golgi 
marker and HDEL (His-Asp-Glu-Leu) that labels ER, partially co-localized with 
these structures (Figure 24).  hStbd1-HA did not co-distribute with microtubules 
as visualized by an antibody against β-tubulin.  Stbd1 tended to be present in 
areas with the densest network of microtubules (Figure 24).   
 
To analyze the role of different domains of Stbd1 in its subcellular distribution, we 
applied mutational analysis.  Removal of the conserved hydrophobic N-terminal 
24 amino acids (ΔN24-HA) resulted in a diffuse cytosolic distribution of Stbd1 as 
well as complete loss of the large perinuclear structures (Figure 23B).  This 
observation indicates that membrane association of Stbd1 is necessary for the 
formation of the enlarged perinuclear structures.  Further N-terminal truncation 
that deletes the putative leucine-zipper domain as well (ΔN90) gave an identical 
pattern (Figure 23C).  These results are consistent with the hydrophobic region 
having an important role in sub-cellular localization, most likely by directing the 
protein to membrane compartments.   
 
At the C-terminus, Stbd1 has a putative carbohydrate binding domain of the 
CBM20 family that we proved its polysaccharide binding ability.  Here we 
analyzed its contribution to the subcellular localization of the protein.  This 
domain is highly conserved in Stbd1 in mammalian species according to our 
protein sequence alignment.  Interestingly, when we removed the carbohydrate 
binding domain (ΔC96), the perinuclear localization is also disrupted (Figure 
23D).  However, compared to that of the N-terminal deletion, the shortened 
protein was distributed in a different way with a more reticular appearance 
perhaps because the loss of the CBM20 domain disabled cargo anchoring and/or 
Stbd1 oligomerization.  Thus, the sub-cellular distribution of C-terminal truncation 
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of Stbd1 may result from nonspecific insertion of Stbd1 into membranes via the 
hydrophobic N-terminus.   
 
Our experiments have not indicated any function for the putative leucine-zipper 
motif in Stbd1.  The yeast two hybrid screen using as bait Stbd1 lacking the 
leucine-zipper region identified Stbd1 as a target, implying that the leucine-zipper 
region is not necessary for Stbd1 oligomerization.  Furthermore, an N-terminal 
truncation removing both the hydrophobic segment and the leucine-zipper 
displayed the same diffuse subcellular distribution as removal of the hydrophobic 
segment alone.    
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Figure 23.  Subcellular localization of Stbd1. 
Mutated hStbd1 with a C-terminal HA-tag was expressed in COS M9 cells and 
immunostained with anti-HA antibodies (red).  (A) Full length human Stbd1.  (B) 
Deletion of the N-terminal hydrophobic segment (ΔN24-HA).  (C) Deletion of the 
N-terminal hydrophobic segment and the putative leucine zipper (ΔN90-HA).  (D) 
Deletion of the C-terminal carbohydrate binding domain (ΔC96-HA.  Nuclei were 
stained with Hoechst (blue). The scale bar is 20 μm.  
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Figure 24.  Subcellular localization of Stbd1 over-expressed in COS M9 
cells with respect to organelle markers. 
Cells overexpressing full-length hStbd1 were immunostained with anti-HA 
antibodies (middle panels) and antibodies towards HDEL as an endoplasmic 
reticulum marker (A, lower panel), towards syntaxin 6 as a Golgi marker (B, lower 
panel) or against β-tubulin as a microtubule marker (C, lower panel).  The upper 
panels show merges of the images, with Stbd1 (red) and the corresponding 
organelle marker (green), with nuclei stained with Hoechst (blue).  The scale bars 
are 20 μm.  
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2.4 Glycogen association of Stbd1 in cells and study of glycogen binding 
site on Stbd1 
 
Though various lines of evidence indicate a correlation between Stbd1 and 
glycogen, it is important to directly demonstrate this association in a cellular 
environment.  It is difficult to find a good cell line to further analyze co-localization 
of glycogen and Stbd1 by light microscopy since most cultured cells do not 
accumulate substantial amounts of glycogen that can be visualized by light 
microscopy.  Therefore, we utilized Rat1WT4 cells which stably overexpress wild 
type rabbit muscle glycogen synthase [217].  The Rat1Neo5 cells described 
earlier were control cells made in the same study by transfection with empty 
vector.  When grown under normal conditions of 25 mM glucose, glycogen could 
be detected in the Rat1WT4 cells by periodic acid/Schiff (PAS) staining, 
visualized as very large deposits, usually no more than a few per cell and 
proximal to the nucleus (Figure 25A).  These large glycogen deposits were 
observed to co-localize with Stbd1 (Figure 25B) using the modified method that 
combines PAS and immunefluorescent staining on the same fixed sample [220].  
When we incubated the Rat1WT4 cells in glucose free medium for 24 hours after 
initial growth in medium with 25 mM glucose, the massive glycogen deposits 
dissipated into much smaller but more numerous punctate PAS-positive 
structures that showed substantial co-localization with Stbd1 (Figure 25A and B).  
Immunofluorescent staining for GS in Rat1WT4 cells gave a clear ring-like 
appearance in many cells and the enzyme was visualized coincident with the 
massive glycogen deposits in an enclosure way (Figure 25C).  In some cases, 
the GS defined a loop within which neither Stbd1 nor PAS-positive material was 
detected, as though the glycogen had been evacuated at some stage along with 
the Stbd1, leaving the GS behind.   
 
In order to study the glycogen binding site of Stbd1, point mutants of Stbd1 were 
also constructed, in which a highly conserved Trp (W293 in human) in the 
CBM20 domain was replaced by either Gly or Leu with the objective of disabling 
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glycogen binding.  W293 was selected for two reasons.  Firstly, three conserved 
tryptophans within CBM20 have been suggested as critical amino acids for 
polysaccharide binding and W293 aligns with the first pivotal tryptophan of 
binding site 1 which has been suggested as the primary recognition site of starch 
in GA SBD from A. niger, the best studied CBM20 structure.  Secondly, unlike 
most proteins containing CBM20s which are microbial origin, Stbd1 and laforin 
are two mammalian proteins that contain CBM20.  A mutation at the 
corresponding conserved W32 in the laforin CBM20 domain, W32G, had been 
found in a Lafora patient and shown not to bind to glycogen [225, 226].  The 
W293G and W293L mutants appeared perinuclear without causing the formation 
of the larger and more well-defined structures seen with the wild type protein 
(Figure 26). 
 
From our experience, PAS staining does not readily detect the low level of 
glycogen normally present in Rat1Neo5 or COS M9 cells, most likely due to its 
dispersed distribution throughout the cells.  However, in COS cells 
overexpressing Stbd1 showing the perinuclear structures described above, 
punctate glycogen deposits were highlighted by PAS staining (Figure 27A).  The 
total glycogen levels in COS cells measured biochemically was unchanged by 
over-expression of Stbd1 (Figure 27B).  When medium lacking glucose replaced 
the normal medium, the PAS-positive structures dissipated consistent with the 
glycogen being degraded as an energy source (Figure 27A).  Meanwhile, the 
combination of immunofluorescent staining for Stbd1 and PAS staining for 
glycogen demonstrated their co-localization in these perinuclear structures 
(Figure 28).  In contrast, although the W293G and W293L mutants were readily 
detected in a perinuclear location, as in Figure 26, no signal for PAS staining was 
detected with mutant proteins (Figure 28), suggesting that the mutant Stbd1 was 
unable to co-localize with glycogen.  W293 aligns to one of the pivotal Trp 
residue in the microbial starch binding site I and W32 that is required for 
glycogen binding in mammalian protein laforin.  Hence, the slightly different 
appearance between the hStbd1-HA and W293G-HA or W293L-HA positive 
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structures is probably due to the absence of glycogen.  Therefore, we infer that 
the glycogen is concentrated by Stbd1 in these perinuclear structures. 
 
 
Figure 25.  Co-localization of Stbd1 with glycogen in Rat1 cells. 
(A) Rat1WT4 cells grown under normal glucose (25 mM; left panel) or starved (0 
glucose; right panel) conditions for 24h were stained with periodic acid/Schiff 
reagent (PAS) to visualize glycogen (pink) by light microscopy.  Arrowheads 
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indicate examples of glycogen staining. (B) Co-localization of endogenous Stbd1 
protein and glycogen. Rat1WT4 cells were grown as in (A), subjected to PAS 
staining to visualize glycogen (upper panels) followed by immunofluorescent 
staining to detect Stbd1 (lower panels).  Arrowheads indicate examples of the co-
localization of glycogen and Stbd1.  (C) Rat1WT4 cells were immunostained for 
Stbd1 (middle panel) and glycogen synthase (GS) (right panel). The merged 
image shows Stbd1 (red) and GS (green) with nuclei stained with Hoechst (blue). 
 
 
 
 
Figure 26.  Point mutational analysis of Stbd1 expressed in COS M9 cells.   
(A) Mutation of conserved Trp of CBM20 domain to Gly (W293G).  (B) Mutation 
of conserved Trp of CBM20 domain to Leu (W293L).  Nuclei were stained with 
Hoechst (blue). The scale bar is 20 μm. 
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Figure 27.  Detection of glycogen in COSM9 cells with or without 
overexpressing Stbd1. 
(A) COS M9 cells overexpressing human Stbd1 (hSTBD1-HA) were incubated in 
medium with 25 mM glucose (upper panel) or no glucose (lower panel) for 24h 
and stained with PAS to visualize glycogen by light microscopy.  Arrow heads 
indicate examples of glycogen staining in the fed cells.  (B) Glycogen content in 
COSM9 cells with or without overexpressing hStbd1-HA.    
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Figure 28.  Co-localization of Stbd1 with glycogen in COS cells.   
COS M9 cells were over-expressed with full length human Stbd1 (hSTBD1-HA; 
left panels) or the CBM20 point mutants (W293G-HA; middle panels and W293L-
HA; right panels).  Cells were subjected to PAS staining to visualize glycogen 
under bright field (upper panels) followed by immunofluorescent staining with 
anti-HA antibodies to visualize Stbd1 under fluorescent channel (lower panels).  
Arrowheads in the lower panels indicate Stbd1 localization and, in the upper 
panels, the colocalized glycogen staining with full length Stbd1.  The scale bars 
are 20 μm.  
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3. Stbd1 interacting proteins  
 
As we learned from our study that Stbd1 binds and tracks glycogen in cells, 
understanding the glycogen trafficking mechanism was our next goal.  We used 
yeast two hybrid screen to identify potential interacting proteins of stbd1.  Using 
Stbd1 lacking the first 171 residues as bait, several interesting targets were 
picked from a human skeletal muscle cDNA library, including four Stbd1 clones 
of different lengths as mentioned before, two autophagy related proteins, 
GABARAP and GABARAPL1, the glycogen phosphatase laforin .and a 
transcription factor cut-like homeobox 1.  
 
3.1 Interaction of Stbd1 with GABARAPL1 and/or GABARAP 
 
The same yeast two hybrid screen that suggested Stbd1 oligomerization also 
identified GABARAP and GABARAPL1 as potential interacting proteins.  These 
two small proteins are members of the ATG8 family that are involved in 
autophagy [179, 213].   
 
3.1.1 Confirmation of interaction 
 
The interaction of Stbd1 with each protein was confirmed by co-
immunoprecipitation of the proteins expressed with epitope tags tags in COS 
cells (Figure 29), whether the pull-down was of the ATG8 protein via an N-
terminal Flag tag or of Stbd1 via a C-terminal HA tag.  A recent proteomic 
analysis of human proteins involved in autophagy also reported interaction of 
Stbd1 with GABARAP and GABARAPL1 [167].   
 
Immunofluorescent staining of co-expressed proteins in COS cells indicated a 
strong co-localization of hStbd1-HA with Flag-GABARAPL1 in the perinuclear 
structures described above (Figure 30A).  There was some co-localization of 
Stbd1-HA with Flag-GABARAP but not as consistently or as strictly as with Flag-
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GABARAPL1 (Figure 30A).  To confirm the interaction of GABARAPL1 with 
Stbd1, we also analyzed the sub-cellular distribution of endogenous 
GABARAPL1.  In cells transfected with control vector, GABARAPL1 showed a 
punctate appearance throughout the cytosol (Figure 30B).  When hStbd1-HA 
was overexpressed, endogenous GABARAPL1 was restricted to the perinuclear 
structures (Figure 30B), similar to what was seen with Flag-GABARAPL1 over-
expression (Figure 30A).  Endogenous LC3, another member of the Atg8 family, 
however, gave a weak signal and did not co-localize with overexpressed Stbd1 
(Figure 30C) which indicated that the interaction of Stbd1 and GABARAPL1 
could be specific.  
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Figure 29.  Interaction of Stbd1 with GABARAPL1 and GABARAP.   
hStbd1 with a C-terminal HA-tag, N-terminal Flag-tagged GABRAPL1 and N-
terminal Flag-tagged GABARAP were expressed alone, or in the indicated 
combination in COS M9 cells.  Control cells were transfected with empty pcDNA3 
vector (Vector).  (A) Immunoblotting of the cell lysates with the indicated antibody.  
(B) Immunoprecipitation of GABARAP (left) or GABARAPL1 (right) with Anti-Flag 
antibodies covalently bound to agarose followed by immunoblotting with the 
indicated antibody.  (C) Immunoprecipitation of Stbd1 with anti-HA antibodies 
covalently bound to agarose followed by immunoblotting with the indicated 
antibody.  
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Figure 30.  Subcellular localization of GABARAPL1, GABARAP and LC3 in 
relation to Stbd1.   
(A) C-terminal HA-tagged hStbd1 was co-expressed in COS M9 cells with N-
terminal Flag-tagged GABARAPL1 or GABARAP, as in Figure, and 
immunostained with anti-HA antibodies (red) or anti-Flag antibodies (green).  (B) 
HA-tagged Stbd1 or N-terminally truncated Stbd1 was expressed in COS M9 
cells and immunostained with anti-HA antibodies to detect Stbd1 (red) and anti-
GABARAPL1 antibodies to visualize endogenous GABARAPL1 (green). The 
bottom row shows cells transfected with empty vector (pcDNA3) to reveal the 
endogenous GABARAPL1 distribution (green).  (C) HA-tagged Stbd1 was 
expressed in COS M9 cells and immunostained with anti-HA antibodies (red) or 
anti-LC3 antibodies (green) to detect endogenous LC3. Nuclei were stained with 
Hoechst (blue).  The scale bar is 20 μm. 
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3.1.2 Identification of Atg8 family interacting motifs on Stbd1 
 
Studies have shown that proteins interact with Atg8 family proteins via Atg8 
family interacting motif, the AIMs, typically a WxxL-like sequence [213] (Figure 8).  
To further understand the structural basis of Stbd1 and GABARAPL1 and/or 
GABARAP interaction, several putative AIMs in Stbd1 were identified, localized 
throughout the sequence (Figure 31) based on the basic sequence pattern. 
 
Using the truncation mutants we already constructed, we were able to narrow 
down the possible region of Stbd1 that mediates the association with autophagy 
related proteins.  In the same COSM9 cell system, Flag-GABARAPL1 was co-
expressed with Stbd1 mutant ΔN24-HA removing the N-terminus or ΔC96-HA 
lacking the C-terminus.  The immunoprecipitaion results indicated that neither the 
N-terminal hydrophobic segment nor the C-terminal CBM20 domain of Stbd1 is 
required for its association with GABARAPL1 since both mutants were able to 
co-immunorecipate with this Atg8 family member just like the full length protein 
(Figure 32).  Furthermore, an immunofluorescent experiment revealed that the 
hStbd1 mutant ΔN24-HA abolished the protein accumulation in the perinuclear 
structures as shown before (Figure 23B) but still co-localized with endogenous 
GABARAPL1 (Figure 30B), consistent with the yeast two-hybrid screen in which 
GABARAPL1 was identified using N-terminally truncated Stbd1 as the bait.  
Moreover, analysis of the Stbd1 sequence for inherent disorder using the 
predictors of natural disordered regions (PONDR) algorithm [227] suggested that 
the entire region between the N-terminal hydrophobic segment and the C-
terminal CBM20 domain has a high probability of disorder and possibly an 
increased possibility of being involved in protein-protein interactions interaction.  
As more and more Atg8 family interacting proteins have been identified and 
studied, the AIM can be refined as x-3x-2x-1W/F/Yx1x2L/I/V, where X1 and/or X2 
and at least one of X-3-X-2-X-1 would be acidic residues  
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At this point, there remained three possible AIMs, SRSYSEV , HEEWEMV 
(W203 and V206 in human Stbd1) and HSSWGDV (W212 and V215 in human 
Stbd1) in the middle of Stbd1 protein sequence.  The SRSYSEV sequence was 
excluded because it was poorly conserved in different species (Figure 19).  
W203, V206 and W212 are invariant in all 16 mammalian Stbd1 protein 
sequences in our alignment.  V215 is also highly conserved in the alignment, with 
only 4 out of 16 exceptions, but the Val residue was replaced by Ile, another 
large hydrophobic residue (Figure 19).  Therefore, we constructed a deletion 
Δ198-222 that removed the conserved region containing both putative AIMs of 
Stbd1, two double mutations, W203A+V206A and W212A+V215A and four single 
point mutations, W203A, V206A, W212A and V215A, hoping to define the 
interaction site(s) (Figure 14).  All the mutants had HA tag at their C-termini like 
the full length protein that we had studied.  Each mutants was individually 
overexpressed in COSM9 cells and the familiar perinuclear enlarged vesicle-like 
structure was observed (Figure 33).   
 
In the immunoprecipitation as well as immunoflurorescent staining experiments, 
Flag-GABARAPL1 was co-expressed with each mutant.  First, the partial deletion, 
Δ198-222-HA lost the ability to co-immunoprecipitate with Flag-GABARAPL1 
(Figure 34) and the following immunofluorescent staining of the two proteins 
showed no co-localization (Figure 35B) even though Δ198-222-HA appeared in 
the familiar perinuclear structures.  When the two double mutations were applied 
in these tests, only (W203A+V206A)-HA reproduced what we observed with 
Δ198-222-HA (Figure 35C).  (W212A+V215A)-HA acted like wild type full length 
Stbd1-HA (Figure 35D).  Mutation of either W203 or V206 in Stbd1 is sufficient to 
eliminate GABABARAL1 association (Figure 36A and B).  In contrast, the other 
single mutants W212A-HA and V215A-HA behaved like wild-type Stbd1, in terms 
of subcellular co-localization with Flag-GABARAPL1 (Figure 36C and D).  The 
W293G-HA, point mutation in CBM20 domain showed different perinulcear 
pattern comparing to wild type Stbd1, but kept the co-locolization with Flag-
GABARAPL1 (Figure 36E), suggesting the loss of interaction is specific.  
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Furthermore, the endogenous GABARAPL1 showed similar distribution pattern to 
Flag-GABARAPL1 overexpression in cells.  It was no longer co-localized with 
Δ198-222 HA and (W203A+V206A)-HA while remained coincident with 
(W212A+V215A)-HA (Figure 37).  These data indicates that WEMV (203-206) 
acts as AIM on Stbd1 for GABARAPL1 interaction. 
 
3.2 Potential interaction between Stbd1 and laforin 
 
Another interesting protein target identified from the same yeast two hybrid 
screen is the glycogen phosphatase laforin which also has a CBM20 domain, 
although in this case at its N-terminus.  When co-expressed with Flag-laforin in 
COSM9 cells, hStbd1-HA co-immunoprecipitated Flag-laforin.  However, pull-
down of laforin did not give co-immunoprecipitation of hStbd1-HA. Stbd1 
oligomerizes via its CBM20 domain and perhaps interacts with laforin via a 
similar interaction.  Then, HA antibodies binding to the C-terminal HA tag of 
hStbd1 might interfere with its association with laforin.  In immunofluorescent 
staining data, Flag-laforin was not consistently present in the perinuclear 
structures of hStbd1-HA, possibly because laforin targets cytosolic glycogen with 
preference to membrane-bound glycogen.  More work is needed to understand 
whether there is any interaction between Stbd1 and laforin, though it would not 
be unreasonable since Stbd1 binds preferentially to phosphorylated glycogen 
that is presumably a substrate for laforin. 
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Figure 31.  Schematic architecture of human Stbd1 with potential AIMs.   
 
 
 
 
Figure 32.  Interaction of GABARAPL1 with truncated mutants of Stbd1. 
Truncated hStbd1 lacking 1-24 residues or 262-358 residues with a C-terminal 
HA-tag (ΔN24-HA or ΔC96-HA) and N-terminal Flag-tagged GABRAPL1 were 
expressed alone, or in the indicated combination in COS M9 cells.  Control cells 
were transfected with empty pcDNA3 vector (Vector).  (A) Immunoblotting of the 
cell lysates with the indicated antibody.  (B) Immunoprecipitation of GABARAPL1 
with Anti-Flag antibodies covalently bound to agarose followed by 
immunoblotting with the indicated antibody.   
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Figure 33.  Mutational analysis of Atg8 family interacting motif (AIM) on 
Stbd1 expressed in COS M9 cells.   
Mutated hStbd1 with a C-terminal HA-tag was expressed in COS M9 cells and 
immunostained with anti-HA antibodies (red).  (A) Full length human Stbd1 (left 
panel) and hStbd1 lacking 198-222 residues (right panel).  (B) Mutations at the 
first potential AIM on Stbd1: double mutation (W203A+V206A-HA) and two single 
mutations (W203A-HA and V206A-HA).  (C) Mutations at the second potential 
AIM on Stbd1: double mutation (W212A+V215A-HA) and two single mutations 
(W212A-HA and V215A-HA).  Nuclei were stained with Hoechst (blue).  The 
scale bar is 20 μm.   
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Figure 34.  Interaction of GABARAPL1 with Stbd1 and potential Atg8 family 
interacting motif (AIM) mutants of Stbd1.   
hStbd1, full length or mutants lacking 198-222 residues or double point mutations 
at potential AIM with a C-terminal HA-tag (Δ198-222-HA or W203A+V206A-HA, 
W212A+V215A-HA) and N-terminal Flag-tagged GABRAPL1 were expressed 
alone, or in the indicated combination in COS M9 cells.  Control cells were 
transfected with empty pcDNA3 vector (Vector).  (A) Immunoblotting of the cell 
lysates with the indicated antibody (left panels).  (B) Immunoprecipitation of 
GABARAPL1 with Anti-Flag antibodies covalently bound to agarose followed by 
immunoblotting with the indicated antibody (right panels).  
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Figure 35.  Subcellular localization of GABARAPL1 and Atg8 family 
interacting motif (AIM) mutants of Stbd1 co-expressed in COS M9 cells. 
Mutated hStbd1 with a C-terminal HA-tag was co-expressed in COS M9 cells 
with N-terminal Flag-tagged GABARAPL1 and immunostained with anti-HA 
antibodies (red) or anti-Flag antibodies (green).  (A) Co-localization of hStbd1 
and GABARAPL1 (merged in left panel) in cells co-expressing C-terminal HA-
tagged full length hStbd1 (middle panel) and N-terminal Flag-tagged 
GABARAPL1 (right panel).  (B) Loss of co-localization (merged in left panel) of 
Flag-tagged GABARAPL1 (right panel) with potential AIM deletion mutant of 
hStbd1, Δ198-222-HA (middle panel).  (C) Impaired co-localization (merged in 
left panel) of Flag-tagged GABARAPL1 (right panel) with double mutation in 
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potential AIM on hStbd1, (W203A+V206A)-HA (middle panel).  (D) Unaffected 
co-localization (merged in left panel) of Flag-tagged GABARAPL1 (right panel) 
with double mutation in another potential AIM on hStbd1, (W212A+V215A)-HA 
(middle panel).  Nuclei were stained with Hoechst (blue).  The scale bar is 20 μm. 
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Figure 36.  Subcellular localization of GABARAPL1 and single mutants of 
Stbd1 co-expressed in COS M9 cells.   
Mutated hStbd1 with a C-terminal HA-tag was co-expressed in COS M9 cells 
with N-terminal Flag-tagged GABARAPL1 and immunostained with anti-HA 
antibodies (red) or anti-Flag antibodies (green).  (A) and (B) Impaired co-
localization (merged in left panels) of Flag-tagged GABARAPL1 (right panels) 
with W203A-HA or V206A-HA (middle panels) which contains single mutation 
within potential AIM on hStbd1.  (C) and (D) Unaffected co-localization (merged 
in left panels) of Flag-tagged GABARAPL1 (right panel) with W212A-HA or 
V215A-HA (middle panels) which contains single mutation within another 
potential AIM on hStbd1.  (E) Co-localization (merged in left panels) of Flag-
tagged GABARAPL1 (right panel) with W293G-HA (middle panels) containing 
point mutation within CBM20 domain on hStbd1.  Nuclei were stained with 
Hoechst (blue).  The scale bar is 20 μm. 
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Figure 37.  Subcellular localization of endogenous GABARAPL1 and 
overexpressed Stbd1 with Atg8 family interacting motif (AIM) mutations in 
COS M9 cells. 
Overexpressed full length or mutated hStbd1 with a C-terminal HA-tag and 
endogenous GABARAPL1 in COS M9 cells was immunostained with anti-HA 
antibodies (red) or anti-GABARAPL1 antibodies (green).  (A) Co-localization of 
hStbd1 and GABARAPL1 (merged in left panel) in cells expressing C-terminal 
HA-tagged full length hStbd1 (middle panel) and endogenous GABARAPL1 (right 
panel).  (B) Loss of co-localization (merged in left panel) of endogenous 
GABARAPL1 (right panel) with potential AIM deletion mutant of hStbd1, Δ198-
222-HA (middle panel).  (C) Impaired co-localization (merged in left panel) of 
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endougenous GABARAPL1 (right panel) with double mutation in potential AIM on 
hStbd1, (W203A+V206A)-HA (middle panel).  (D) Unaffected co-localization 
(merged in left panel) of endougenous GABARAPL1 (right panel) with double 
mutation in another potential AIM on hStbd1, (W212A+V215A)-HA (middle panel).  
Nuclei were stained with Hoechst (blue).  The scale bar is 20 μm. 
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DISCUSSION 
 
1. Involvement of Stbd1 in glycogen metabolism   
 
The primary conclusion from this study is that Stbd1 is involved in glycogen 
metabolism.  Data collected in several experiments using independent 
approaches support this suggestion.  We hypothesize that the two most obvious 
and highly conserved domains of Stbd1, the N-terminal hydrophobic 24 residues 
and the C-terminal CBM20 domain, serve to anchor glycogen to membranous 
structures.  That the N-terminal hydrophobic segment causes membrane 
association of Stbd1 is supported by two lines of evidence.  First, in muscle 
extracts, Stbd1 is solubilized from the LSP by non-ionic detergents during 
fractionation to isolate glycogen.  Second, Stbd1 was present in large perinuclear 
vesicle-like structures and the removal of its N-terminus significantly alters the 
sub-cellular localization to a diffuse cytosolic distribution.  The CBM20 domain at 
the C-terminus of Stbd1 suggests the ability to bind polysaccharide and is 
supported by several experiments.  First, recombinant Stbd1 co-sedimented with 
glycogen or the chemically related polysaccharide amylopectin in vitro.  Second, 
when non-ionic detergent was present to disrupt membranes when muscle 
extracts were prepared, there was still a substantial proportion of Stbd1 
recovered in the HSP where the glycogen is concentrated, suggesting the co-
sedimentation of Stbd1 with glycogen is independent of membrane association.  
These results suggest that Stbd1 physically interacts with glycogen in vitro and in 
mouse muscle extracts.  Third, in the cell models, such as Rat1WT4 cells or 
COSM9 cells over-expressing Stbd1, where we could visualize accumulated 
glycogen by PAS staining, Stbd1 was consistently co-localized with glycogen.  
Further evidence for Stbd1 binding to glycogen in cells was provided by analysis 
of point mutations of Stbd1 W293, a conserved residue in the CBM20 domain 
thought to be important for carbohydrate binding.  Although over-expressed 
Stbd1 mutants retained a perinuclear staining pattern for Stbd1, the glycogen 
was no longer co-localized as judged by PAS staining.  The Stbd1-positive 
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perinuclear structures were not seen at all when Stbd1 lacking the CBM20 
domain was expressed.  These results are consistent with Stbd1 tethering 
glycogen to membranes in cells.  In other experiments, a genetic link between 
Stbd1 and glycogen was indicated since Stbd1 protein level decreased when 
glycogen was genetically reduced in mouse muscle or liver.  Other glycogen 
binding enzymes, such as GS and laforin, have reduced protein levels 
accompanying genetic depletion of glycogen [86, 228], probably because the 
binding to glycogen increases the stability of these glycogen associated proteins. 
 
Taking account of these various experimental results, we propose that Stbd1 
binds to glycogen by its C-terminal CBM20 domain and interacts with 
membranes via its hydrophobic N-terminus, thus anchoring glycogen to 
subcellular membranous structures involving in glycogen metabolism (Figure 31).   
 
Glycogen metabolism can not only be influenced by the regulation of principal 
metabolic enzymes like GS and GPh, but can also be affected by the glycogen 
size, subcellular localization and its interaction with numerous proteins of 
glycogen metabolism [8].  Although glycogen has been studied for decades, 
there are still many unanswered questions, for instance, where do glycogen 
particles assemble?  The membrane tethering ability of Stbd1 could therefore be 
involved in determining the location of glycogen synthesis and glycogen particles 
have been identified in proximity to ER or SR membranes from electronic 
microscopic data [17, 18] as mentioned in the introduction.  Furthermore, in 
skeletal muscle, the SR localization of glycogen has been suggested as allowing 
ATP production at sites close to where it is needed for muscular activity [2].  
During exercise especially high intensity exercise, continued muscle contractions 
depend on ATP generated from glycolytic pathway where a large proportion, up 
to 80% of utilized glucose derives from glycogenolysis.  Hence, Stbd1 could 
assist in localization of glycogen in metabolically useful sites.  In fact, in the 
original paper describing Stbd1, the protein was reported to localize to T-tubules 
and the sarcoplasmic reticulum of skeletal muscle [161].  Another process that 
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potentially involves a membrane localization of glycogen is its transport to 
lysosomes (Figure 2), a process which is clearly demonstrated by the phenotype 
of GSD-II (Pompe disease) but still not well understood.  A notable feature of 
skeletal muscle pathology in Pompe patients is increased autophagy so that the 
disease is also categorized as an autophagic vacuolar myopathy [229].  In 
mouse models of the disease, glycogen is also accumulated in autophagosome-
like vesicles or late endosomes as well as lysosomes, which indicates the 
involvement of intracellular trafficking of glycogen within vesicles [229].  A 
reasonable explanation for the phenomena in both human patients and mouse 
models is that defective lysosomal disposal of the glycogen leads to the backing 
up of cargo vesicles delivering glycogen.  Stbd1 could be a critical player in this 
vesicular trafficking process by tethering polysaccharide molecules to 
membranes.   
 
2. Stbd1 as a selective autophagic adaptor for glycogen disposal 
 
The participation of Stbd1 in vesicular trafficking of glycogen is also supported by 
its interaction with GABARAPL1 and to a lesser extent GABARAP which are 
present in the perinuclear Stbd1-positive and glycogen-enriched structures.  
Furthermore, Stbd1 bears the specific and conserved sequence, AIM/LIR, which 
mediates interaction of cargo receptor and Atg8 family proteins in selective 
autophagy process.  Deletion or point mutations of the AIM/LIR in Stbd1 has no 
effect on Stbd1 subcellular localization, but results in the loss of protein-protein 
interaction with GABARAPL1, and hence GABARAPL1 is no longer coincident 
with the perinuclear Stbd1-positive structures.  As noted in the Introduction, 
autophagy can be a selective rather than a totally random process.  Depending 
on target cargo, there are various selective autophagy pathways such as 
aggrephagy, pexophagy, mitophagy, reticulophagy, ribophagy, lipophagy and 
xenophagy.  To date, only three mammalian proteins have been proposed as 
autophagic cargo receptors.  SQSTM1/p62 and NBR1 mediate trafficking of 
ubiquitin-modified substrates by binding to LC3.  BNIP3L/Nix participates in 
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mitophagy through two pathways.  One is ubiquitin-independent pathway in 
which BNIP3L/Nix interacting with LC3/GABARAP proteins especially 
GABARAPL1.  In the other pathway, BNIP3L/Nix involves in translocation of E3 
ligase Parkin to the membrane of damaged mitochondria and the Parkin-
mediated ubiquitination recruits SQSTM1/p62 for subsequent transport [194]. 
 
Glycogen autophagy has been discussed in a limited number of reports, where it 
was observed in skeletal muscle [230], liver and heart [231] of newborn animals 
that require extensive energy in postnatal metabolism during the period of after 
birth until the start of suckling [68].  It has been proposed that in newborns, the 
glycogen autophagy works in addition to the phosphorolytic degradation of 
glycogen to oppose hypoglycemia.  Meanwhile, the process has been suggested 
to depend on the cAMP-PKA pathway and to be under negative control of the PI-
mTOR pathway [67, 68].  However, little is known about glycogen autophagy in 
adult animals. 
 
We propose that Stbd1 acts as a glycogen receptor interacting with GABARAPL1 
and possibly with GABARAP, thereby participating in the autophagic transfer of 
glycogen to the lysosome (Figure 31).  Since the classic autophagosome marker 
LC3 was not coincident with Stbd1, this vesicular trafficking process is probably 
distinguished from the canonical autophagy pathway though there may still be 
involvement of normal macroautophagic machinary.  In addition, phospholipid 
modified GABARAP has been suggested to be a critical element in basal 
autophagy independent of mTOR inactivation [189].  Therefore, Stbd1-
GABARAPL1/GABARAP may play a housekeeping role in cell metabolism, 
selectively disposing polysaccharides.  In our experiments, overexpression of 
Stbd1 in cells leads to the accumulation of the large perinuclear structures 
containing glycogen and positive for GABARAPL1 along with Stbd1.  These 
enlarged structures, somewhat similar to what is seen in GSD-II (Pompe 
disease), may represent accumulated vesicular and glycogen intermediates 
caused by an overload of the normal trafficking pathway for glycogen 
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degradation via the lysosome.  We also showed in our data that Stbd1 binds 
better to plant amylopectin or glycogen from Epm2a -/- mice, both of which are 
less branched than normal glycogen, similar to the polyglucosans related to other 
glycogen storage diseases, such as GSD-IV (Andersen disease or adult 
polyglucosan disease) and GSD-VII (Tarui disease) [232].  Moreover, in some 
muscle cells from Epm2a-/- and Epm2b-/- mice, Stbd1 detected by 
immunohistochemical staining showed coincidence with Lafora bodies reflected 
by PAS staining after diastase treatment.  Aberrant glycogen obviously need to 
be removed from cells, hence Stbd1 could selectively target such abnormal 
polysaccharides for lysosomal clearance via intracellular vesicular delivery.  In a 
proteomic analysis of lysosome-related organelles, Stbd1 was not identified in 
lysosomes but rather an endosomal fraction instead [233].  This observation 
would be consistent with lysosomal degradation of Stbd1.  In summary, our 
hypothesis is that glycogen is tethered by Stbd1 to membranes where a vesicle 
is formed to transport glycogen to lysosomes, with the recruitment of 
GABARAPL1 or GABARAP, as these vesicles mature prior to lysosomal fusion 
(Figure 38).    
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Figure 38.  Working model.   
Stbd1 acts as a selective autophagic adaptor for glycogen disposal.  Stbd1 
targets glycogen and tethers it to membranes where a vesicle is formed to 
transport glycogen to lysosomes for lysosomal degradation, with the recruitment 
of GABARAPL1 or GABARAP, as these vesicles mature prior to lysosomal fusion.   
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